



Review

A critical review of the role of M₂PYK in the Warburg effect[☆]

Robert A. Harris, Aron W. Fenton*

Department of Biochemistry and Molecular Biology, The University of Kansas Medical Center, Kansas City, KS 66160, United States



A B S T R A C T

It is becoming generally accepted in recent literature that the Warburg effect in cancer depends on inhibition of M₂PYK, the pyruvate kinase isozyme most commonly expressed in tumors. We remain skeptical. There continues to be a general lack of solid experimental evidence for the underlying idea that a bottle neck in aerobic glycolysis at the level of M₂PYK results in an expanded pool of glycolytic intermediates (which are thought to serve as building blocks necessary for proliferation and growth of cancer cells). If a bottle neck at M₂PYK exists, then the remarkable increase in lactate production by cancer cells is a paradox, particularly since a high percentage of the carbons of lactate originate from glucose. The finding that pyruvate kinase activity is invariably increased rather than decreased in cancer undermines the logic of the M₂PYK bottle neck, but is consistent with high lactate production. The “inactive” state of M₂PYK in cancer is often described as a dimer (with reduced substrate affinity) that has dissociated from an active tetramer of M₂PYK. Although M₂PYK clearly dissociates easier than other isozymes of pyruvate kinase, it is not clear that dissociation of the tetramer occurs *in vivo* when ligands are present that promote tetramer formation. Furthermore, it is also not clear whether the dissociated dimer retains any activity at all. A number of non-canonical functions for M₂PYK have been proposed, all of which can be challenged by the finding that not all cancer cell types are dependent on M₂PYK expression. Additional in-depth studies of the Warburg effect and specifically of the possible regulatory role of M₂PYK in the Warburg effect are needed.

1. Introduction

Many researchers have concluded that the pyruvate kinase (PYK) reaction, the last reaction in glycolysis, plays a pivotal role in controlling metabolism in cancer tissues. In fact, even in 1975 it was known that tumor cell respiration can be stimulated by the use of PYK inhibitors [46,47]. More recent discussions on the controllers of Warburg metabolism often reference Christofk, *et al.* to indicate PYK's role in tumor growth [48]. Given the appeal of targeting Warburg metabolism to treat cancer and the growing acknowledgment of the role of M₂PYK in controlling that metabolism, it is not surprising that there has now been considerable effort to directly target M₂PYK activity for drug design [49–68].

Unfortunately, the race to identify a M₂PYK-targeting cancer drug has led to several poorly supported explanations for how M₂PYK functions in cancer and many of those explanations are based on data that have not been fully scrutinized (or speculated ideas that were never supported by data!). Therefore, the goal of this review is to critically evaluate M₂PYK functions in the context of Warburg metabolism. However, rather than simply dismiss M₂PYK as an important enzyme in Warburg metabolism, we conclude with a speculation about the role of increased glycolysis in cancer metabolism.

2. A quick overview of PYK

Historically, the unique properties of the pyruvate kinase protein in cancers were identified simultaneously with isozyme expression patterns in normal tissues [75–84]. There are four isozymes expressed in mammals [75,87,88]. LPYK (found in liver and pancreas) and PYK from erythrocytes (R-PYK) are products of one gene as a result of alternative start sites [89–93]. M₁PYK (found in heart, muscle and brain and characterized by a hyperbolic response of activity over a concentration range of PEP) and M₂PYK (also referred to as KPYK due to its presence in kidney and characterized by a sigmoidal response of activity over a concentration range of PEP), originate from a second gene *via* alternative RNA splicing [75,87,88,96,97], and differ by only 22 amino acids. In early fetal tissue, M₂-PYK is the only isozyme detected. Near the time of birth, expression of M₂PYK is displaced by tissue specific isozymes in many tissues [75,88,100,101]. Despite this general trend for a change in isozyme expression, several adult tissue types continue to express M₂-PYK, including adult lung, kidney and many smooth muscle organs [75,88,100,104–106]. Re-expression of M₂PYK is an early event in transformation of normal tissue into cancer [112]; therefore, the serum level of M₂PYK has been evaluated as a marker for many types of cancers [113–115]. These well-established facts about

[☆] Research in the Fenton laboratory is supported by NIH grant GM115340 and a pilot grant from the KUMC PKD Center (DK106912) and the KU Cancer Center and a pilot award from the KUMC Alzheimer's Disease Center (AG035982).

* Corresponding author at: The University of Kansas Medical Center, Biochemistry and Molecular Biology, MS 3030, 3901 Rainbow Boulevard, Kansas City, KS 66160, United States.

E-mail address: afenton@kumc.edu (A.W. Fenton).

<https://doi.org/10.1016/j.bbcan.2019.01.004>

Received 8 November 2018; Received in revised form 14 January 2019; Accepted 14 January 2019

Available online 29 January 2019

0304-419X/ © 2019 Elsevier B.V. All rights reserved.

Table 1
Properties of pyruvate kinase isozymes in the absence of regulators.

	M ₁ PYK	LPYK	RPYK	M ₂ PYK (normal tissue)	M ₂ PYK (cancer tissue or cell)
In the absence of regulators^a					
Specific Activity ^b	230-780	60-560	60-300	130-500	770
K_M or $S_{0.5}$ PEP (mM)	0.04-0.09	0.3-1.0	0.5-0.6	0.09-0.4 ^c	0.4
K_M ADP(mM)	0.3-0.4	0.1-0.6	0.4-0.6	0.2-0.4	??
Full ranges when including outcomes of regulations					
Specific Activity ^b	Unregulated	Unregulated	Unregulated	34-500 ^f	??
K_M or $S_{0.5}$ PEP (mM)	Unregulated ^d	0.02-10 ^e	??	0.078-3.0 ^f	??
Allosteric regulations					
Allosteric activator (lowest effective conc.)	None	Fru-1,6-BP (0.00006 mM) ⁿ	Fru-1,6-BP (0.003mM) ^o	Fru-1,6-BP (0.00005 mM) ^l	Fru-1,6-BP (0.00005 mM) ^h
				Serine (0.8mM) ^m	Serine ??
				SAICAR (0.1mM) ^p	SAICAR ??
Allosteric inhibitor (lowest effective conc.)	Phenylalanine ^d (5mM)	Alanine (0.5mM) ⁿ	Alanine	Phenylalanine (0.4mM) ^m	Phenylalanine (4.8mM) ^h
				Alanine (0.8mM) ^m	Alanine ??
					Cystine (0.05mM) ^g
Physiological range^s					
	Normal tissues		Cancer tissues		
Intracellular pH	7.0-7.2 ⁱ		7.12-7.65		
phosphoenolpyruvate	0.0035-0.397 μ mole/g fresh wt ^j		1.02 x normal ^q		
Fru-1,6-BP	0.009-0.120 ^j μ mole/g fresh wt ^{j,k}		0.99 x normal ^q		
Serine	0.19-1.27 μ mole/g fresh wt ^j		1.26 x normal ^q		
Alanine	0.38-1.64 μ mole/g fresh wt ^j		1.01 x normal ^q		
Phenylalanine	7.87 nmol/10 ⁶ cells ^f		1.82 x normal ^q		

^aData in this section are from [88,89,252] and represents a summary of findings from many studies and from multiple mammalian species.

^bSpecific activity is the number of μ moles of pyruvate formed per min per mg of enzyme.

^cRange expanded based from 0.2–0.4 reported in [88] down to 0.09–0.4 based [123].

^dThe affinity of M₁PYK for the allosteric inhibitor, phenylalanine, is low at pH values below 7.5 [124]. Therefore, under normal physiological conditions, this enzyme may not be regulated and values are the same as in the absence of regulators. Phenylalanine concentration that produces an effect [124,253].

^eThe highest value is in the presence of alanine and the lowest is in the presence of Fru-1,6-BP, however, these values are dependent on pH (7.5 used as the upper limit for considerations here), monovalent cation type, divalent cation type, and ion concentrations [254,255].

^fA phenylalanine-dependent decrease in specific activity was reported in [143] but not in [177].

^gAlthough inhibition is shown, estimation of PEP affinity in the presence of Cys was not included. [130].

^h Like control of M₁PYK activity by phenylalanine, the concentration required to inhibit M₂PYK is likely above the physiological range. [82].

ⁱ[256–258].

^jData are from [259] and represent a summary of findings from many studies and from many mammalian tissues.

^kExcludes the very low concentration of 0.0009 (μ mole/g fresh wt.) found in adipose.

^l[116].

^m[143,253].

ⁿ[89,254].

^o[260,261].

^p[262].

^q[156].

^r[263].

^sGiven that the cell is 70% water, μ mole/g fresh wt \div 0.7 approximates the mM concentration.

M₂PYK set a background for the discussion of a role of M₂PYK in Warburg metabolism.

3. M₂PYK in cancer tissue/cells is NOT an “inhibited” isozyme of pyruvate kinase

The often-repeated assumption that the M₂PYK present in cancer cells is an inhibited form of pyruvate kinase seems to have been derived from a comparison of the enzymatic properties of M₂PYK to those of M₁PYK [96,97]. Indeed, in the absence of post-translational modifications, protein:protein interacting partners, or allosteric effectors, M₁PYK has a lower higher apparent affinity (*i.e.*, We use apparent affinity to refer to the concentration of substrate at $\frac{1}{2} V_{max}$ activity. For a sigmoidal response fit to the Hill equation, this parameter is sometimes referred to as $S_{0.5}$ or $K_{0.5}$. When data are hyperbolic, the parameter is a K_M . Our use of apparent affinity is intended to collectively refer to both.) for the substrate, phosphoenolpyruvate (PEP), compared to M₂PYK (Table 1) [88,123]. In addition, M₁PYK is often used in comparative studies of an enzyme that increases flux through the PYK reaction [48]. However, when considered in the context of all the various types of regulatory mechanisms that can alter substrate affinity, it is better to state that M₂PYK has a larger range of substrate affinities that can be accessed *via* various regulatory mechanisms. In contrast, inhibition by hydrophobic amino acids is the only regulatory mechanism for M₁PYK [124] and given the low affinities for these ligands, it is unclear if the collective concentration of all hydrophobic amino acids provides a mechanism for control of M₁PYK that is physiologically meaningful. (M₁PYK often is reported as not being allosterically regulated.) Unfortunately, in this comparison to M₁PYK, the “tunability” of M₂PYK’s affinity for PEP seems to have been completely overlooked in the assignment of M₂PYK as “inhibited.”

In fact, a decrease in the apparent affinity of M₂PYK does not in itself imply reduced PYK activity in the cell. A few different scenarios (or combinations of these) could result in the same or increased activity in the cell, despite a reduced substrate affinity for one isozyme. For simplicity in these hypothetical considerations, we will consider a true K_M instead of an $S_{0.5}$. 1) The activity in a cell depends upon the cellular concentration of substrate. If PEP concentrations are sufficiently high relative to K_M values for both isozymes, both the M₁PYK and M₂PYK enzymes could have the same level of catalytic turnover, despite differences in K_M (Fig. 1). 2) If an isozyme with lower substrate affinity




Fig. 2. Synthetic Data for two isozymes with altered K_M and enzyme increased enzyme concentration and/or increased V_{max} activity to demonstrate the possibility that an isozyme with lower substrate affinity can give rise to higher activity even at sub-saturating substrate concentrations, if it also has either higher specific activity or if it is expressed at higher concentrations.

also has a higher V_{max} , then the cell could have equal or higher activity compared an enzyme with tighter substrate affinity, but lower V_{max} activity (Fig. 2). 3) When an enzyme with lower substrate affinity (*e.g.*, M₂PYK) is expressed at higher concentrations in the cell, the cell can have equal or higher total activity compared to when an isozyme with higher substrate affinity (*e.g.*, M₁PYK) is expressed at a lower concentration. Therefore, an isozyme switch to an enzyme with a reduced substrate affinity does not imply reduced enzyme activity and metabolic flux in the cell (Fig. 2). Therefore, the reduced affinity of M₂PYK for PEP, when compared to M₁PYK does not imply reduced PYK activity in the cell.

Despite the often-quoted idea that M₂PYK is inhibited, the similar kinetic/enzymatic properties of M₂PYK, LPYK, and RPYK (in the absence of any other regulatory mechanism) give little reason to consider M₂PYK to be “inhibited” [88,128]. LPYK and M₂PYK have similar apparent affinities for PEP and similar specific activity values in the absence of regulatory effectors. Despite the M₂PYK vs. LPYK similarities,




Fig. 1. Synthetic data for two isozymes with different K_M values as a demonstration that reduced substrate affinity of an isozyme alone is not sufficient to predict activity in the cell. If substrate concentrations are sufficiently high in the cell (indicated by gray column) two isozymes with different affinity for substrate can give rise to the same level of activity. The Michaelis Menten equation was used to generate synthetic data in the left panel here and in Figs. 2, and 4. Data in the left panel are hyperbolic (consistent with M₁PYK data) on a linear x-axis, but appear sigmoidal in this figure due to the logarithmic scale of the x-axis. Data in the middle panel were derived from the Hill equation (with a n_H value equal to 3). The resulting sigmoidal response is more representative of that found for M₂PYK. The panel on the right compares a hyperbolic response with a higher substrate affinity (representing M₁PYK) to a sigmoidal response with a lower substrate affinity (representing M₂PYK). As exemplified in this figure, the ideas discussed in the text can be represented by the simpler comparison of hyperbolic data. Therefore, all other figures in this review include only data generated from the simpler Michaelis Menten equation. Nonetheless, the reader should keep in mind that M₂PYK has a sigmoidal response.

the LPYK expressed in hepatocytes is displaced by M₂PYK expression in hepatocarcinomas, much like M₂PYK expression is favored in most other cancer tissues. Therefore, pointing to the apparent affinity of M₂PYK for PEP (in the absence of effectors) as the primary property that makes M₂PYK important for cancer survival seems unwarranted. Furthermore, if comparisons between isozymes can be used to define one isozyme as inhibited or not inhibited and given that LPYK is not commonly referenced as an “inhibited” form, then the LPYK vs. M₂PYK comparison would support that M₂PYK is also not inhibited.

Many past reviews of the role of M₂PYK in cancer biology have focused primarily on the isozyme expression switch that results in M₂PYK being expressed in cancer tissues. However, that focus overlooks the fact that M₂PYK is expressed in several normal adult tissues (e.g., lung, kidney, many smooth muscles) [75,100,104–106]. An isolated focus on the PYK isozyme expression switch also ignores the evidence that the “cancer” form of M₂PYK has properties that differ from those of M₂PYK expressed in normal adult tissues [82,128–140]. A search of the primary literature for direct comparisons of the kinetic/enzyme properties of M₂PYK isolated from normal vs. from cancer tissue/cells reveals relatively few studies. Nonetheless, those reports that are available indicate that the M₂PYK isolated from cancer has higher (NOT lower) affinity for PEP when compared to M₂PYK isolated from normal tissue [128,138,141]. In total, there is very little evidence to support the often-repeated idea that M₂PYK isolated from cancer cells is inhibited.

4. Focusing on functional outcomes of regulatory mechanism is more important than focusing on tetrameric M₂PYK dissociating into dimer/monomer

At the protein level *in vitro*, the M₂PYK subunits exist in an equilibrium between a tetramer and dimers/monomers. The observations of a quaternary structure change *in vitro*, with knowledge that dissociated dimers of other PYK isozymes lack activity, have led to the acceptance that M₂PYK can easily be inhibited. In fact, that idea can be extended as a mechanism of control if the percentage of the protein that exists in each quaternary state can be modulated by the various regulatory mechanisms: post translational modifications (PTMs), protein:protein interactions, or small molecule allosteric effectors [6,34,39,44,142–151].

It is often assumed that any reference to “inhibition” of M₂PYK implies a dimeric state of the enzyme. However, it is important to note that there are many examples of enzymes/binding proteins that are inhibited (with altered substrate affinity or altered k_{cat}) without multimeric dissociation. Therefore, the focus in the literature on a potential M₂PYK dimer-tetramer equilibrium may be overemphasized. What is more relevant to metabolism are the maximal enzymatic capacity in the cell (which intrinsically includes enzyme expression level), the specifics of whether the regulatory mechanism alters substrate affinity and/or specific activity of M₂PYK and how those two ideas combine to determine the metabolic flux through the PYK reaction in the cell.

In fact, the ability of enzyme expression levels to influence the metabolism flux through the PYK reaction in the cell depends on whether a given regulatory mechanism alters the enzymes K_M for substrate or prevents catalytic turnover. To exemplify this concept, consider the potential of M₂PYK becoming inhibited in cancer (the common consideration in much of the literature). More specifically, if the “inhibited” form of M₂PYK only has reduced substrate affinity, then upon a switch from M₁PYK expression to M₂PYK in cancer, the reduced affinity would initially cause reduced flux through the PYK reaction and a build-up of up-stream glycolytic intermediates (Fig. 3). However, once concentrations of PEP increase sufficiently (due to reduced activity at low concentrations of PEP), that increased substrate availability would drive flux through the pyruvate kinase reaction. Therefore, the new steady-state would include high concentrations of metabolites upstream of the PYK reaction, but would also include flux

through the PYK reaction to result in the observed increased lactate production. In this scenario, the concentration of the M₂PYK enzyme would also influence the rate of flux through the PYK reaction. In turn, it would be the build-up of glycolytic intermediates that would provide us with the most reasonable explanation for why a lack of a Pasteur effect and a high rate of glycolysis even under aerobic conditions may be beneficial to dividing cells. Due to increased substrate availability (i.e., glucose-6-phosphate), flux through the pentose phosphate pathway would be increased. The pentose phosphate pathway is largely responsible for producing the NADPH needed to regenerate the antioxidant glutathione and permit cancer cells to live with the increased oxidative stress known to exist in cancer. It follows in this logic that the rate of flux through the PYK reaction at the bottom of glycolysis influences NADPH production in the pentose phosphate pathway. This scenario emphasizes a new steady-state condition to explain a high rate of glycolysis and that new steady-state would be associated with an increase in concentrations of glycolytic intermediates, but would also allow lactate production. That new steady-state could include cancer-specific rates of glycogen turnover [152–154]. As noted, overexpression of M₂PYK in this scenario could also result in increased glycolytic flux. Importantly, the scenario presented in Fig. 3 is used to explain common ideas about Warburg metabolism rather than what is actually supported by data, which is that the activity of PYK is increased rather than decreased in cancer cells [128,138,141,155].

As a further contrast, a comparison of tumor tissue with non-tumor esophageal tissue failed to identify the increase in glycolytic intermediates [156] that would be anticipated by the scenario in Fig. 3. Although it is generally thought that most lactate is derived from glycolysis [109,157,158], Fig. 3 also does not consider that lactate can be derived from the metabolism of glutamine or serine [158–164]. Therefore, although Fig. 3 offers an explanation that circumvents the apparent paradox introduced by M₂PYK “inhibition” vs. increased lactic acid production, the entire assumption of the M₂PYK inhibition is what should be questioned. Despite the lack of support in cancer metabolism, the description in Fig. 3 is not completely useless in that it is consistent with the increased levels of glycolytic intermediates identified for metabolism in other tissues that result in high levels of lactate production (e.g., ischemia in the brain and electroshock-induced seizures in the brain.) [165,166]. Furthermore, there are indications for variable metabolism used by different types of cancer [167–169], leaving the possibility open that there may be a unique type of cancer that uses the scenario described in Fig. 3.

In contrast to a K-type regulation represented in Fig. 3, if “inhibition” of M₂PYK means that the enzyme lacks catalytic turn over, then a regulatory mechanism that shifts M₂PYK towards the inhibited form would reduce flux through the PYK reaction step, even when intermediate metabolite concentrations are increased. If indeed, the M₂PYK in cancer lacks or has greatly reduced catalysis (Fig. 4), then the only way to gain flux through the PYK reaction is to activate the enzyme. Even higher levels of enzyme expression would have no relevance if that enzyme has a complete lack of activity. If indeed Warburg metabolism includes both increased levels of glycolytic intermediates and increased lactate production as commonly reported, then the dynamic balance between k_{cat} -activated and k_{cat} -inhibited forms of M₂PYK would be challenging to explain.

Despite this thought exercise that can provide an explanation for how a reduced substrate affinity for M₂PYK in cancer (a commonly repeated theme in the literature) could provide a description of why M₂PYK could dictate Warburg metabolism, it is contrary to data that indicates increased PYK activity in cancer [128,138,141,155]. Fructose-1,6-bisphosphate (Fru-1,6-BP) causes an approximately 8-fold increase in the apparent affinity for PEP [148,170]. This change is also associated with a doubling of the V_{max} . This change in catalytic activity does not imply a complete lack of catalysis in the non-activated or inhibited form(s), but does suggest that changes in both specific activity and substrate affinity contribute to activation/inhibition.




Fig. 3. A role for altered affinity of cancer M_2PYK for PEP in creating a new steady-state in Warburg metabolism. The top panel represents the activity response curves of either normal PYK or cancer M_2PYK . “Normal” PYK can be M_1PYK , L_{PYK} , R_{PYK} , or M_2PYK isolated from normal tissue. Concentrations of PEP in the cell are represented by red boxes and the respective PYK activity at that PEP concentration is represented by black dashes intersecting the red box (also marked with letters A and B at the beginning and the two steady-state PYK activities) and the response curve. The blue arrows trace changes related to the progression to cancer: 1) The PYK isozyme changes to cancer M_2PYK , which has little activity at the PEP concentration present in normal tissue. 2) PEP concentrations build up due to reduced PYK activity. 3) Due to increased substrate availability caused by PEP build up, the cancer form of M_2PYK has activity at high PEP. This condition maintains high levels of glycolytic intermediates and allows for high flux to lactic acid production. Green arrows connect the two steady-state PYK activities (A and B) with panels representing the respective metabolism. In these two lower panels, the thickness of arrows is intended to represent the relative concentrations of intermediates in the pathway indicated by the respective arrow. Left) When normal PYK is expressed, normal metabolism is at a steady-state and in the presence of O_2 , that steady-state flux of carbon from sugar into the mitochondria for oxidative phosphorylation. Right) When cancer M_2PYK is expressed, a new steady-state flux is established that includes higher concentrations of glycolytic intermediates. This includes high rates of flux through the cancer PYK reaction and increased production of lactic acid. We anticipate higher flux through the mitochondria as well, thus generating higher levels of reactive oxygen species (ROS) and oxidative stress. However, the increased concentration of glucose 6-phosphate in the new steady-state condition drives increased flux through the pentose phosphate pathway due to substrate availability. This change produces increased NADPH. NADPH is needed to regenerate glutathione, which counteracts the increased oxidative stress, thus allowing cancer cells to live with higher intracellular ROS concentrations.

5. M_2PYK tetramer-dimer equilibrium may not have physiological relevance

Unfortunately, in the studies of M_2PYK , there has been considerably more focus on the tetramer dissociation upon “inhibition” than providing the clear characterizations of the functional/enzymatic outcomes associated with the form of M_2PYK found in cancer. Nonetheless knowing what causes the tetramer to dissociation has the potential to indirectly contribute to our knowledge of functional outcomes if the functional properties of the dissociated dimer are well characterized. This conversation can be initiated by evaluating if there is convincing data that the M_2PYK dimer retains activity, and even that conversation should be preceded with a cautionary note derived from previous

studies of M_1PYK .

Many more protein denaturation and refolding studies have been completed with M_1PYK than with M_2PYK . For the M_1PYK protein, denaturation progresses from the stable tetramer to an expanded tetramer, to an inactive dimer before further unfolding steps are observed. The observation of the stable dimer is relevant to our current consideration [171–174], given the focus on the tetramer to dimer transition in studies of M_2PYK in cancer. However, indications that the dimeric form of M_1PYK is active are thought to be artifacts because PEP stabilizes the tetrameric form of that enzyme [173,175,176]. Therefore, even when isolated dimers of the M_1PYK protein are added to an assay, the presence of PEP in the assay causes dimers to rapidly assemble into active tetramers. Thus, the study of M_1PYK exemplifies that an inactive




Fig. 4. A theoretical response curve of normal PYK and cancer M_2 PYK, if “inhibited” cancer M_2 PYK involves reduced k_{cat} . Here 5% activity compared to Normal PYK is used as an example, although the points in the text are more relevant if inhibition removes all catalytic activity. “Normal” PYK can be M_1 PYK, LPYK, RPYK, or M_2 PYK isolated from normal tissue. In the absence of changes in M_2 PYK expression, the only way to increase flux through the PYK reaction would be to activate the M_2 PYK protein, thus requiring a dynamic control of M_2 PYK to achieve both inhibition for build-up of glycolytic intermediates and to allow sufficient flux through the PYK reaction to generate high levels of lactic acid. The need for that dynamic regulation might predict oscillating flux of high glycolytic intermediate dispersed with periods of high lactic acid production.

dimeric form of a protein can easily be misinterpreted to have enzymatic activity. The conclusion of studies of M_1 PYK is that the dimeric form of the enzyme is not catalytically active.

Keeping in mind the lesson learned from studies of M_1 PYK, it is important to note that both substrates of the enzyme, ADP and PEP, stabilize the M_2 PYK tetramer [145,177]. However, given that M_2 PYK isolated from cancer cells/tissues has properties that are different from M_2 PYK isolated from normal tissue [82,128–140], a more specific consideration of M_2 PYK isolated from cancer may be warranted. Like the M_1 PYK form, there is a rapid re-association of dimers of the cancer form of M_2 PYK when PEP is present [149]. For all conditions studied, Hofmann *et al.* and co-workers found evidence for activity for the dimer, leading them to consider the dimeric form of cancer- M_2 PYK to be “suboptimal” (without specifying if that implied reduced k_{cat} or reduced substrate affinity) [145,149,150]. Assays of the isolated dimer produced activity in the Mazurek laboratory [178], but for the reason identified in the M_1 PYK example, without evidence that the protein maintains a dimer form in all assay conditions, data collected from that design does not actually support that the dimer maintains activity.

Several studies probe M_2 PYK structure function questions with mutations, but they do not always define if the mutations cause the protein to behave like the M_2 PYK from normal tissues vs. from cancer tissues. For example, the G415R mutant dimer fails to tetramerize in the presence of Fru-1,6-BP but shows activity: again, the influence of PEP in the assay condition on tetramerization was not evaluated [179]. In contrast to any indication that the dimer retains activity, a K305Q mutation that prevent tetramer formation is reported to “abolish activity” [170].

More direct data indicate that detection of dimer forms of M_2 PYK do not correlate with cell proliferation [180]. Finally, the argument has recently been made that cellular concentrations of Fru-1,6-BP, an allosteric activator that promotes both high PEP affinity and stabilization of the tetrameric state of M_2 PYK, are sufficiently high to predict that unmodified M_2 PYK (presumably equal to that found in normal tissue) is

always a tetramer in the cell [147]. Therefore, despite what is often reported, there is little to no evidence that establishes that the M_2 PYK dimer does or does not retain activity

Also relevant to this topic, several studies have reported the use of antibodies to detect specific oligomeric states of M_2 PYK (e.g., [181]). However, antibody binding to a given multimeric form of an antigen protein that is in equilibrium with some other multimeric form will of necessity influence the equilibrium of the subunit assemblies. Even in tissues that have been crosslinked (i.e., samples for histological analysis), tetramer dissociation to dimer may be possible. The idea that antibody binding causes dissociation might best be supported by considering that an antibody that specifically recognizes the monomers of M_2 PYK promotes dissociation into monomers [51,144] in the same way that antibodies to dimers identifies dissociation into dimers. Furthermore, antibody staining is not quantitative: if the percentage of M_2 PYK in the dimer form of M_2 PYK changes from 0.0001% of the total M_2 PYK protein to 0.0003%, then stated in isolation, a 3-fold change would sound important. However, the percentage of the total protein that is under consideration is so small as to make the observation seem negligible. For these reasons, antibodies detection of dimeric M_2 PYK should be used with extreme caution.

Overall, the M_2 PYK tetramer dissociates *in vitro* into dimers and monomers much easier than other isozymes of PYK [144,145,148,149,170]. It follows that it is challenging to prove that M_2 PYK dimers exist in cells, especially given the influence of various ligands and molecular crowding to promote subunit association. At least in normal tissue, and possibly in cancer tissue, dissociation may not have a physiological relevance due to ligand concentrations [147].

6. Level of M_2 PYK protein/mRNA expression and maximal enzyme capacity of the PYK reaction

Up to now, the distinction between responses to regulatory mechanisms has been emphasized. In particular, if response does not completely eliminate catalysis, then total activity levels can influence metabolic flux. It follows that a modification in the level of enzyme expression is one conceivable way to control total PYK activity. The level of M_2 PYK protein is upregulated in many cancer cell types, which is consistent with upregulation of the mRNA encoding the protein [182–186]. However, that upregulation is often offset by the loss of expression of some other tissue specific isozyme [75,187]; therefore, protein expression of M_2 PYK alone may not correlate with an increase in total PYK activity in cancer. Furthermore, expression levels of M_2 PYK are not likely to correlate with cancer progression for those cancer types that are derived from normal tissues, which already express M_2 PYK [188,189]. If a given range of PYK activity is what is needed for cancer metabolism, then it follows that excess PYK activity provided by some other PYK isozyme may also support rapid cell proliferation, which, in turn, may be the bases of several observations that suggest the M_2 PYK isozyme is not required in all types of cancers [190–195].

Despite that the level of M_2 PYK contribution to total PYK activity may depend on cell type, the “maximum enzyme capacity” for the PYK activity is increased in cancer cells [128,138,141]. Furthermore, increased pyruvate kinase activity (and other glycolytic enzyme activities) has been correlated with the growth rate of tumors/malignancy [141,155]. This correlation again indicates more PYK activity in rapidly growing tumors, not inhibition of PYK.

7. Post translational modifications of M_2 PYK in cancer

Although we can clearly question the representation that M_2 PYK is “inhibited” and the “evidence” that a tetramer/reduced-activity-dimer equilibrium is central to a regulatory mechanism of M_2 PYK *in vivo*, we accept that PYK is a control site in glycolysis [10,11]. (Although this too has been questioned in the context of cancer *via* flux analysis [196,197].) It also remains that forced expression of M_1 PYK in place of

Table 2
PTMs identified on M₂PYK (or a MPYK isozyme without distinguishing between M₁PYK and M₂PYK).

PTM type	Amino acid residue location if known	Ref
Glycosylation		[1,2]
O-GlcNAc (Serine/threonine)	403 and 405	[3–6]
O-methylation (glutamic acid/aspartic acid)		[7]
Oxidation	358	[8]
Methylation (arginine)	445, 447 and 455	[9]
MARlation		[10]
N-acetylserine	2	Uniprot HPRD
N6-acetyllysine	3, 62, 89, 135, 162, 166, 206, 207, 230, 266, 305, 433 and 498	Uniprot HPRD PhosphoSitePlus [13–18]
Nitrosylation (cysteine)	49	HPRD
Nitrosylation (tryptophan)		[19]
Nitrosylation (tyrosine)		[20,21]
Phosphorylation (serine/threonine)	37, 41, 45, 50, 57, 60, 77, 80, 87, 93, 95, 97, 100, 127, 129, 172, 195, 202, 222, 243, 249, 287, 328, 437 and 454	Uniprot HPRD PhosphoSitePlus [22–38]
Phosphorylation (tyrosine)	83, 105, 148, 149, 175, 370, 390 and 466	Uniprot HPRD PhosphoSitePlus [30,39–45]
Sumolation		[94]
Succinylation (lysine)	62, 66, 115, 135, 247, 311, and 498	[95]
Ubiquitination (lysine)	66, 115, 125, 136, 141, 151, 166, 186, 188, 206, 224, 261, 277, 311, 322, 336, 367, 475	PhosphoSitePlus [98,99]
4-hydroxylation (prolines)	403 and 408	Uniprot and [70]
Prolyl isomerization		[102,103]

M₂PYK limits xenograph tumor growth [15] and activation of M₂PYK suppresses tumor growth [26]. Therefore, M₂PYK continues to be central in cancer biology and it is worth exploring what properties may be unique in cancer to cause this cancer-central role.

Again, M₂PYK in cancer cells is modified compared to M₂PYK in normal tissues [82,128–140]. The early techniques used to identify these differences included isoelectric focusing, making it reasonable that the observed alterations at the protein level could be due to PTMs. Unique substrate affinities for the M₂PYK protein purified from normal vs. cancer tissue could also be interpreted as consistent with PTMs that are unique in cancer [128]. As exemplified by the observation that phosphorylation promotes the dimer form of M₂PYK [39,142], modification by PTMs may work in concert with other regulatory mechanisms. Recent literature record a large number of post-translational modifications on M₂PYK [198] and many more are included in the various data banks (Table 2).

Unfortunately, the studies of many of these PTMs fall well short of satisfying what, if any, role they play in cancer metabolism. 1) The influence on the metabolic activity of M₂PYK or their influence on cancer biology has not been detailed for most PTMs that have been identified. There are, however, some exceptions with more information available [9,15,23,34,35,39,44,45,98]. 2) Most, if not all, of these PTMs were identified from cancer cell lines. Because only a small fraction of cells from a cancer tumor are capable of being developed into a cell line, it remains unknown if regulatory mechanisms for M₂PYK identified in cell lines represent those that are the most abundant in tumors. 3) Many of these PTMs were originally identified on fragments of the M₂PYK protein as detected by mass spectrometry. This identification approach does not distinguish if the PTMs can be added to the whole protein or if they are added to peptide fragments that result from protein degradation. Due to the high sequence similarity, this approach also fails to distinguish if the modification was present on only M₂PYK, only M₁PYK, or both. If modifications can be added to both isozymes, then a stream of questions follow (e.g., Can the PTM be added to both M₁PYK and M₂PYK? Does the PTM regulate the two enzymes the same way? etc.). 4) Finally, the mass spectrometry techniques used to identify modifications on peptide fragments are very sensitive, leaving the possibility that modifications are only added to a negligibly small fraction of the total M₂PYK present in the cell. If only a few molecules of M₂PYK include a given PTM, it would be hard to imagine a regulatory role for that PTM. Even though the field seldom acknowledges that many of the identified PTMs may not have physiological roles, it remains plausible that PTMs may contribute to the unique properties of

M₂PYK found in tumors.

8. Allosteric Regulation of M₂PYK by small molecule effectors

It is well established that the response of M₂PYK to allosteric effectors differs from that of other mammalian PYK isozymes [88,89,101,106,136,138,139,199–202]. This includes the allosteric activation by Fru-1,6-BP that results in an increased affinity of M₂PYK for PEP, and alanine and phenylalanine, both allosteric inhibitors that decrease affinity of the enzyme for PEP. Although these responses are qualitatively shared with LPYK, the concentrations and the resulting substrate affinities with effector bound are unique for the two enzymes.

Yuan *et al.* recently extended the characterizations of amino acid regulators of M₂PYK [143]. They found that in addition to phenylalanine and alanine, tryptophan, methionine, valine, and proline acted as allosteric inhibitors. The ability of hydrophobic amino acids to act as inhibitors parallels the response from M₁PYK [124]. However, these inhibitory effects on M₂PYK appear to be within concentration ranges that are more relevant to physiological conditions. Consistent with earlier studies [148,170], inhibitions by amino acids were reported to include change in both V_{max} and substrate affinity for PEP. Histidine and serine acted as activators in the Yuan *et al.* study. The activation by serine only increased V_{max} without influencing substrate affinity. Importantly, these influences of allosteric amino acid effectors were measured with an M₂PYK protein expressed in *E. coli* that would lack any cancer-specific PTMs.

Regulation by L-cysteine and L-serine can be further highlighted. An inhibition by L-cysteine [139,140,203] appears to be unique to the M₂PYK purified out of cancer cells [128]. L-cysteine reduces both V_{max} and the apparent affinity for PEP. [138]. L-serine has been known to be an activator of M₂PYK for some time [135,148,204,205], with some evidence for a differential response between the normal and cancer enzymes from chicken.

ATP is often listed as a common allosteric inhibitor of mammalian PYK isozymes. However, without a binding site identified *via* co-crystallography, it has been challenging to establish whether the inhibition is allosteric or *via* competitive binding with ADP in the active site. Nonetheless, the cancer form of M₂PYK has been reported to lack sensitivity to ATP, in contrast to the ATP inhibition that is observed for M₂PYK isolated from normal tissue [206].

Succinyl-5-amino imidazole-4-carboxamide-1-ribose-5'-phosphate (SAICAR), an intermediate of the *de novo* purine nucleotide biosynthesis pathway activates M₂PYK, but not M₁PYK [207]. SAICAR

Table 3
Proteins reported to interact directly with M₂PYK.

DAPk	[11]
DDB2	[12]
HERC1	[69]
HIF-1 α	[70]
HPV-16 E7	[71]
HSP40	[72]
HSP90	[24]
JMJD5	[73]
JMJD8	[74]
MDM2	[85]
MST1	[86]
Oct-4	[107]
PanK4	[108]
PHD3	[70,109]
Phosphotyrosine peptide	[110,111]
PML	[116]
PRLr	[117]
p53	[118]
SOCS3	[119]
SREBP	[120–122]
SUMO-E3 Ligase PIAS3	[94]
TGIF2	[125]
TRIM35	[126]
TSC22DS	[127]

concentrations are reported higher in cancer cells than normal cells that express M₂PYK (*i.e.*, lung fibroblasts). It remains undefined if SAICAR causes a change in specific activity or modifies substrate affinity.

9. M₂PYK metabolic functions regulated by protein:protein interactions

A number of proteins that interact directly with the M₂PYK protein have been identified in recent years (Table 3). In those studies, it is not always clear if the proposed protein:protein interactions are thought to alter metabolic functions *via* enzyme activity in the cytosol or *via* nuclear functions (see below). However, some studies have directly tested the influence of protein:protein interactions on the metabolic activity of M₂PYK. Interactions of M₂PYK with tyrosine-phosphorylated peptides, SOCS3, PRL, JMJD8 causes reduced PYK activity [74,110,117,119]. In contrast, interaction of M₂PYK with DAPk results in increased PYK activity [11]. Although thought to occur in the cytoplasm, the influence of a direct interaction with PanK4 and TRIM35 on the activity of M₂PYK was not determined [108,126]. Also, whether altered activities of M₂PYK are a result of changes in specific activity or substrate affinity have not typically been determined for these protein interactions.

Much like PTMs, quantitation is lacking in these protein:protein interaction studies. This begs the question of whether there is a sufficient percentage of M₂PYK in the protein:protein interaction to warrant consideration of that interaction as a regulatory mechanism. It should also be kept in mind that the percentage of each interacting protein that participates in a protein:protein interaction is dependent on the concentrations of both proteins. Therefore, there is a note of caution for all reports of proteins that directly interact with M₂PYK when interactions are detected in systems that overexpress M₂PYK or the other protein, thus artificially driving protein:protein interactions that may not occur at a meaningful level under normal expression levels. Nonetheless, given the examples of protein:protein interactions that can alter M₂PYK metabolic activity, protein:protein interactions may work in concert with PTMs and/or small molecule allosteric ligands to control M₂PYK activity.

10. The role of the affinity of M₂PYK for ADP

Control of metabolic flux via M₂PYK may not depend solely on changes in the enzyme's affinity for PEP. Removal of competition between PYK and mitochondrial oxidative phosphorylation for ADP has

been offered as an explanation for why tumor cell respiration can be stimulated by inhibitors of PYK [46,47].

This idea would require M₂PYK to have a higher affinity for ADP than the mitochondrial electrogenic adenine nucleotide translocator (ANT). In non-proliferating cells, the apparent affinity for ADP reported for PYK isozymes are much lower (200–400 μ M) [88,208] than values reported for ANT in non-proliferating cells (1 to 100 μ M) [209]. In non-proliferating cells, respiration creates a membrane potential and pH gradient across the mitochondrial inner membrane that drives release of ATP in exchange for cytosolic ADP via the electrogenic ANT located in the mitochondrial inner membrane. In turn, this leads to a high cytosolic ATP/ADP ratio and a free ADP concentration (in the range of 25 μ M). That ADP range is considerably below the K_M of PYK, a scenario that restricts PYK flux. Therefore, inhibition of PYK in non-proliferating cells has a reduced effect on the respiration rate.

The conditions are much different in rapidly proliferating cancer cells. In these cells, ATP/ADP exchange is not driven by the electrogenic ANT [210], due to inhibition of the mitochondrial outer membrane voltage-dependent anion channel (VDAC) [211]. This results in a low cytosolic ATP/ADP ratio and therefore a higher free cytosolic ADP concentration that promotes PYK activity, aerobic glycolysis, and the Warburg effect. Since PYK is a major user of ADP in proliferating cells, inhibition of its activity greatly influences the free ADP concentration. When PYK activity is inhibited, the resulting increased free cytosolic ADP concentration overcomes inhibition of the ANT and thereby stimulates respiration. These details are consistent with tumor cell respiration being stimulated by inhibitors of PYK.

11. The influence of M₂PYK on glycolytic flux *in vivo*

Throughout the discussion of M₂PYK as a glycolytic enzyme, it becomes clear that many of the measurements that are easily obtained (maximal enzyme activity in a tissue, enzyme concentrations, mRNA concentrations, responses to substrates, responses to effectors and metabolite concentrations) do not easily translate into knowledge of flux through a pathway *in vivo*. This concept is the bases of flux analysis [212–214], which also includes increasing concentrations of other enzymes in a pathway [215]. Within flux analysis, it is recognized that a change in enzyme activity will both reduce substrate concentration and increase product for that enzymatic step. However, those changes in substrate and product concentrations will alter activity of other enzymatic steps. Thus, the ability of each enzyme to control flux is measured as a “control strength” value instead of attempting to assign a single enzyme as a “rate limiting step” in the pathway. Surprisingly, there are few flux analysis evaluations of the metabolism found in cancer cells and little evidence that M₂PYK is a control point in the flux analysis studies that have been completed [196,197].

Consistent with this lack of evidence for M₂PYK as a control point and inconsistent with the highly popular speculation for inhibition of M₂PYK in cancer, there is little evidence for increased concentrations of glycolytic intermediates in cancer [165,216]. Even in a theoretical consideration, a potential increase in glycolytic intermediates, all of which are phosphorylated, must be limited to prevent depletion of inorganic phosphate: fructose intolerance is caused by phosphate depletion due to the accumulation of fructose 1-phosphate. Of special note is that most flux analysis *via* isotope labeling [217] can identify increased labeling of glycolytic intermediates without evaluating for increases in the concentrations of those glycolytic intermediates.

12. M₂PYK in non-canonical role: nuclear translocation of M₂PYK to act as a protein kinase

Given the many questions that have often challenged a metabolic role for M₂PYK in cancer, it is not surprising that there have been many attempts to identify some function for M₂PYK in cancer that is outside of the traditional metabolic function. These proposed non-canonical/

non-metabolic/moonlighting functions reported for M₂PYK parallel proposals for a non-canonical functions for a large number of other enzymes [218].

Both a PEP-dependent protein kinase activity of M₂-PYK [24,134,151,207,219–229] and a translocation of dimeric M₂PYK into the nucleus to act as a transcription factor [34,73,120,125,230–235] have been proposed for M₂PYK. The protein kinase activity appears to primarily be detected in the nucleus using nuclear proteins as substrates. However, it is less defined if all roles prescribed to the nuclear M₂PYK dimer rely on that proposed protein kinase activity. The nuclear functions of a M₂PYK dimer have been proposed to regulate gene transcription of both glycolytic functions and other cancer-specific properties.

A few considerations introduce a strong caution for the proposed PEP-dependent protein kinase activity. Presumably, the substrate peptide must bind in the nucleotide portion of the active site. However, that nucleotide binding site is similar in all pyruvate kinase isozymes, begging the question of why the other mammalian isozymes do not also have a protein kinase activity. (A protein kinase activity is also reported for yeast PYK [236].) A second caution is derived from the PYK control included in efforts to identify a protein kinase that uses PEP as a phosphate donor [237,238]. In those studies, even in a dialyzed protein extract, there is a probability that assays include contaminating concentrations of both PYK and ADP, resulting in a transfer of a phosphate from PEP to ADP (*via* the PYK reaction) and, in turn, ATP being the true phosphate donor. It follows for studies of M₂PYK as a protein kinase that even undetectable contamination levels of ADP and an ATP-dependent protein kinase could result in substrate protein phosphorylation and be interpreted as a PEP-dependent protein kinase activity for PYK. This becomes increasingly relevant given that cellular concentrations of ADP are largely bound to proteins [208], hence tight binding and a high possibility of proteinaceous extracts including contamination by ADP. It has also been shown that “enzyme cycling” systems, such as the one possible with PYK, ADP and a protein kinase, amplifies signal [239], an outcome that may be relevant if the protein kinase activity for PYK is an artifact due to contamination. Therefore, absolute proof of a protein kinase activity for M₂PYK is challenging. Co-crystallization of a substrate peptide in the active site of M₂PYK would greatly strengthen an argument for M₂PYK acting as a protein kinase. Despite these considerations, there continues to be large numbers of studies reporting detection of protein kinase activity for M₂PYK. However, there has also been a challenge that these protein kinase detections are not reproducible [240].

13. M₂PYK in non-canonical roles: M₂PYK translocation into the mitochondria and circulating in the blood

Several non-canonical functions have been proposed that do not have obvious dependencies on nuclear translocation. It has been proposed that M₂PYK alters mitochondrial fusion *via* a protein:protein interaction with p53 [85,241]. Translocation of M₂PYK into the mitochondria, followed by a protein-protein interaction with and phosphorylation of Bcl2 to regulate apoptosis has also been proposed [229].

M₂PYK circulating in the blood may also have a role in cancer [242,243]. M₂PYK in blood promotes angiogenesis in tumors. Much like other non-canonical functions, this activity is reported to depend on a dimer form of the enzyme. Interestingly, the caveats regarding cellular concentrations of metabolites that were used to question the dissociation of tetramer in the cytoplasm are not likely to apply to dissociation of the M₂PYK tetramer in circulating blood or in other cellular compartments beyond the cytoplasm. Rather than or in addition to circulating M₂PYK, M₂PYK released by neutrophils at a wound site may facilitate angiogenesis [244].

14. Studies of M₂PYK are plagued with a lack of quantitative studies

All non-canonical functions of M₂PYK and many proposed PTM and protein:protein interactions can be collectively questioned by the observation that M₂PYK is not required in all cancer types [190–195]. The recent report that M₁PYK can promote tumor cell growth [195] may offer an even more specific challenge to these proposed non-metabolic/non-canonical roles for M₂PYK in cancer (as well as many of the identified regulatory mechanisms).

A second reason that all of the various PTM, protein:protein interactions and non-canonical functions of M₂PYK can collectively be questioned is the lack of quantitation and good techniques to probe only regulatory features of the M₂PYK protein. Most of these non-canonical functions are heavily influenced by antibody/western blot detection techniques, which will give a result when combined with sensitive chemiluminescent detection (even if they are non-meaningful physiologically). Observations from those non-quantitative antibody-based approaches are often paired with knock-out, knock-down and overexpression strategies, which seldom neatly probe regulatory features, a third reason to question many reported observations. To fully appreciate why changing expression levels is not a good probe of function, consider the role of M₂PYK in controlling glycolytic flux: Would knock-out, knock-down, or overexpression of the enzyme identify if a protein phosphorylation subtly alters glycolytic flux? The answer is no because the entire glycolytic pathway would be perturbed and alterations in many down-stream metabolite would be expected to act as further signals for change. It follows that knock-out, knock-down and overexpression strategies may not be good tools to evaluate the potential roles of non-canonical roles of M₂PYK. Cell culture and *in vivo* studies that include M₂PYK proteins with point mutations that mimic or prevent individual types of the regulatory mechanisms starts to address the need for better probing approaches. However, even that design is challenged: mutant M₂PYK introduced *in vivo* might mimic chronic changes in enzyme function, but they don't recapitulate the reversible acute responses that would be possible with PTMs, allostery, and protein:protein interactions *in vivo*. Therefore, inducible regulatory mechanisms may have an important role in the future [245].

15. What can we speculate about Warburg metabolism based on primary literature

The Warburg effect is the incomplete switch from glycolytic production of lactic acid to complete glucose oxidation when O₂ is present. In other words, the Warburg effect is an incomplete Pasteur Effect, or perhaps even better characterized as rapid glycolysis on top of oxidative phosphorylation [246]. Rather than increasing the concentrations of glycolytic intermediates to force flux (by mass action) into side pathways that are important for cell proliferation and growth, we visualize that increased expression of enzymes at the branch points of these side pathways, namely glucose-6-phosphate dehydrogenase [247] and 3-phosphoglycerate dehydrogenase [248], readily explains increased synthesis of NADPH, ribose 5-phosphate, serine, and glycine. Increased expression of all of the glycolytic enzymes [249], including M₂PYK [216], assures that generation of intermediates of the glycolytic pathway is not rate-limiting for glycolysis as well as the side reactions. We believe the Warburg effect as it relates to glucose metabolism is due to upregulation of the enzymes of the glycolytic pathway coupled with increased expression of pyruvate dehydrogenase kinases [250] to partially inhibit the pyruvate dehydrogenase complex. In turn, this partial inhibition of the pyruvate dehydrogenase complex restricts the levels of pyruvate (a result of increased glycolytic flux) that can enter the citric acid cycle and, instead, conserves sufficient quantities of pyruvate for the recycling of NADH produced by glycolysis back to NAD⁺ (although citric acid cycle continues to function [217,251]). The Warburg effect further depends upon reduced mitochondrial uptake of ADP due to

suppression of the activity of the mitochondrial ANT [210] which decreases the cytosolic ATP/ADP ratio and sets a higher steady state concentration of free ADP required for M₂PK activity as discussed in greater detail above.

16. An explanation for outcomes in studies with M₂PK

Unfortunately, the summary of M₂PK is that there are so many functions and regulatory mechanisms reported for M₂PK (beyond catalysis in glycolysis), that it is easy to question if any of these observations have valid physiological relevance. In particular, the finding that M₂PK is not required for all cancers [190–195] seems to refocus studies on the role of M₂PK back to its metabolic function.

We propose that the many types of potential regulatory mechanisms of M₂PK allows a fine tuning of activity to a level that supports the metabolic flux levels needed for cancer survival. Therefore, drug activation of M₂PK [49–56,61–64] or expression of M₁PK [48] that lacks sensitivity to regulatory mechanisms may introduce too much PK activity, an outcome that would prevent some glucose-6-phosphate from entering the pentose phosphate pathway to produce the required NADPH. This scenario would be toxic to the cell. As a contrast, over-expression of M₂PK can be accommodated because of cellular mechanisms that reduce activity to the cancer-specific activity range. On the other hand, any knock-down, knock-out, or drug designs that inhibit M₂PK activity [59,60,63,65–68] has the potential to reduce the total PK activity below a threshold needed for cell survival.

In Warburg metabolism, increased flux through glycolysis results from additional PK activity, not reduced PK activity. Although we can conceive how that increased flux could be accompanied with increased concentrations of glycolytic intermediates when there is a switch from expression of M₁PK to M₂PK (Fig. 3), we anticipate that many cancer types do not have this phenotypic change (as compared to comparable normal tissue) [156].

Acknowledgments

Research in the Fenton laboratory is supported by NIH grant GM115340 and a pilot grant from the KUMC PKD Center (DK106912) and the KU Cancer Center and a pilot award from the KUMC Alzheimer's Disease Center (AG035982).

References

- [1] F.O. Gbormittah, B.B. Haab, K. Partyka, C. Garcia-Ott, M. Hancapie, W.S. Hancock, Characterization of glycoproteins in pancreatic cyst fluid using a high-performance multiple lectin affinity chromatography platform, *J. Proteome Res.* 13 (2014) 289–299.
- [2] K. O'Connell, P. Doran, J. Gannon, K. Ohlendick, Lectin-based proteomic profiling of aged skeletal muscle: decreased pyruvate kinase isozyme M1 exhibits drastically increased levels of N-glycosylation, *Eur. J. Cell Biol.* 87 (2008) 793–805.
- [3] L. Wells, K. Vosseller, R.N. Cole, J.M. Cronshaw, M.J. Matunis, G.W. Hart, Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications, *Mol. Cell. Proteomics* 1 (2002) 791–804.
- [4] V. Champattanachai, P. Netsirisawan, P. Chaiyawat, T. Phueaouan, R. Charoenwattanasatien, D. Chokchaichamnankit, P. Punyarit, C. Srisomsap, J. Svasti, Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer, *Proteomics* 13 (2013) 2088–2099.
- [5] P. Chaiyawat, D. Chokchaichamnankit, K. Lirdprapamongkol, C. Srisomsap, J. Svasti, V. Champattanachai, Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells, *Oncol. Rep.* 34 (2015) 1933–1942.
- [6] Y. Wang, J. Liu, X. Jin, D. Zhang, D. Li, F. Hao, Y. Feng, S. Gu, F. Meng, M. Tian, Y. Zheng, L. Xin, X. Zhang, X. Han, L. Aravind, M. Wei, O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect, *Proc. Natl. Acad. Sci. U. S. A.* 114 (2017) 13732–13737.
- [7] W. Zhou, M. Capello, C. Fredolini, L. Racanicchi, E. Dugnani, L. Piemonti, L.A. Liotta, F. Novelli, E.F. Petricoin, Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells, *Anal. Bioanal. Chem.* 405 (14) (2013) 4937–4943.
- [8] D. Anastasiou, G. Poulgiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen, G. Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, C.J. Thomas, M.G. Vander Heiden, L.C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses, *Science* 334 (2011) 1278–1283.
- [9] F. Liu, F. Ma, Y. Wang, L. Hao, H. Zeng, C. Jia, Y. Wang, P. Liu, I.M. Ong, B. Li, G. Chen, J. Jiang, S. Gong, L. Li, W. Xu, PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis, *Nat. Cell Biol.* 19 (2017) 1358–1370.
- [10] I. Carter-O'Connell, H. Jin, R.K. Morgan, R. Zaja, L.L. David, I. Ahel, M.S. Cohen, Identifying family-member-specific targets of mono-ARTDs by using a chemical genetics approach, *Cell Rep.* 14 (2016) 621–631.
- [11] I. Mor, R. Carlessi, T. Ast, E. Feinstein, A. Kimchi, Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase, *Oncogene* 31 (2012) 683–693.
- [12] X. Xie, M. Wang, J. Mei, F. Hu, F. Ding, L. Lv, Pyruvate kinase M2 interacts with DNA damage-binding protein 2 and reduces cell survival upon UV irradiation, *Biochem. Biophys. Res. Commun.* 467 (2015) 427–433.
- [13] Y. Xiong, Q.Y. Lei, S. Zhao, K.L. Guan, Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK, *Cold Spring Harb. Symp. Quant. Biol.* 76 (2011) 285–289.
- [14] S. Marimuthu, R.S. Chivukula, L.F. Alfonso, M. Moridani, F.K. Hagen, G.J. Bhat, Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets, *Int. J. Oncol.* 39 (2011) 1273–1283.
- [15] L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, Y. Xu, G. Wang, Y. Huang, Y. Xiong, K.L. Guan, Q.Y. Lei, Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth, *Mol. Cell* 42 (2011) 719–730.
- [16] S. Zhao, W. Xu, W. Jiang, W. Yu, Y. Lin, T. Zhang, J. Yao, L. Zhou, Y. Zeng, H. Li, Y. Li, J. Shi, W. An, S.M. Hancock, F. He, L. Qin, J. Chin, P. Yang, X. Chen, Q. Lei, Y. Xiong, K.L. Guan, Regulation of cellular metabolism by protein lysine acetylation, *Science* 327 (2010) 1000–1004.
- [17] C. Choudhary, C. Kumar, F. Gnäd, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen, M. Mann, Lysine acetylation targets protein complexes and co-regulates major cellular functions, *Science* 325 (2009) 834–840.
- [18] L. Lv, Y.P. Xu, D. Zhao, F.L. Li, W. Wang, N. Sasaki, Y. Jiang, X. Zhou, T.T. Li, K.L. Guan, Q.Y. Lei, Y. Xiong, Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization, *Mol. Cell* 52 (2013) 340–352.
- [19] H. Kawasaki, K. Ikeda, A. Shigenaga, T. Baba, K. Takamori, H. Ogawa, F. Yamakura, Mass spectrometric identification of tryptophan nitration sites on proteins in peroxynitrite-treated lysates from PC12 cells, *Free Radic. Biol. Med.* 50 (2011) 419–427.
- [20] W.N. Kuo, J.M. Kreahling, V.P. Shanbhag, P.P. Shanbhag, M. Mewar, Protein nitration, *Mol. Cell. Biochem.* 214 (2000) 121–129.
- [21] J. Kanski, S.J. Hong, C. Schoneich, Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nano-electrospray ionization tandem mass spectrometry, *J. Biol. Chem.* 280 (2005) 24261–24266.
- [22] N. Koo, K.M. Kim, Distinct effects on M2-type pyruvate kinase are involved in the dimethylsulfoxide-induced modulation of cellular proliferation and degranulation of mast cells, *Arch. Pharm. Res.* 32 (2009) 1637–1642.
- [23] B. Kumar, R.N. Bamezai, Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells, *Mol. Biol. Rep.* 42 (2015) 1317–1321.
- [24] Q. Xu, J. Tu, C. Dou, J. Zhang, L. Yang, X. Liu, K. Lei, Z. Liu, Y. Wang, L. Li, H. Bao, J. Wang, K. Tu, HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma, *Mol. Cancer* 16 (2017) 178.
- [25] J.V. Olsen, B. Blagoev, F. Gnäd, B. Macek, C. Kumar, P. Mortensen, M. Mann, Global, in vivo, and site-specific phosphorylation dynamics in signaling networks, *Cell* 127 (2006) 635–648.
- [26] S.A. Beausoleil, J. Villen, S.A. Gerber, J. Rush, S.P. Gygi, A probability-based approach for high-throughput protein phosphorylation analysis and site localization, *Nat. Biotechnol.* 24 (2006) 1285–1292.
- [27] R.P. Zahedi, U. Lewandrowski, J. Wiesner, S. Wortelkamp, J. Moebius, C. Schutz, U. Walter, S. Gambaryan, A. Sickmann, Phosphoproteome of resting human platelets, *J. Proteome Res.* 7 (2008) 526–534.
- [28] H. Daub, J.V. Olsen, M. Bairlein, F. Gnäd, F.S. Oppermann, R. Korner, Z. Greff, G. Kerl, O. Stemann, M. Mann, Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle, *Mol. Cell* 31 (2008) 438–448.
- [29] N. Dephoure, C. Zhou, J. Villen, S.A. Beausoleil, C.E. Bakalarski, S.J. Elledge, S.P. Gygi, A quantitative atlas of mitotic phosphorylation, *Proc. Natl. Acad. Sci. U. S. A.* 105 (2008) 10762–10767.
- [30] Y. Mayya, D.H. Lundgren, S.I. Hwang, K. Rezaul, L. Wu, J.K. Eng, V. Rodionov, D.K. Han, Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions, *Sci. Signal* 2 (2009) ra46.
- [31] J.V. Olsen, M. Vermeulen, A. Santamaria, C. Kumar, M.L. Miller, L.J. Jensen, F. Gnäd, J. Cox, T.S. Jensen, E.A. Nigg, S. Brunak, M. Mann, Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis, *Sci. Signal* 3 (2010) ra3.
- [32] K.T. Rigbolt, T.A. Prokhorova, V. Akimov, J. Henningsen, P.T. Johansen, I. Kratchmarova, M. Kassem, M. Mann, J.V. Olsen, B. Blagoev, System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation, *Sci. Signal* 4 (2011) rs3.
- [33] S. Siwko, D. Mochly-Rosen, Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase, *Int. J. Biochem. Cell Biol.* 39 (2007) 978–987.
- [34] W. Yang, Y. Zheng, Y. Xia, H. Ji, X. Chen, F. Guo, C.A. Lyssiotis, K. Aldape,

- L.C. Cantley, Z. Lu, ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect, *Nat. Cell Biol.* 14 (2012) 1295–1304.
- [35] Z. Yu, X. Zhao, L. Huang, T. Zhang, F. Yang, L. Xie, S. Song, P. Miao, L. Zhao, X. Sun, J. Liu, G. Huang, Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells, *J. Biol. Chem.* 288 (2013) 35406–35416.
- [36] J. Liang, R. Cao, Y. Zhang, Y. Xia, Y. Zheng, X. Li, L. Wang, W. Yang, Z. Lu, PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis, *Nat. Commun.* 7 (2016) 12431.
- [37] K.M. Lee, K. Nam, S. Oh, J. Lim, T. Lee, I. Shin, ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2, *Cell. Signal.* 27 (2015) 228–235.
- [38] Y.S. Park, D.J. Kim, H. Koo, S.H. Jang, Y.M. You, J.H. Cho, S.J. Yang, E.S. Yu, Y. Jung, D.C. Lee, J.A. Kim, Z.Y. Park, K.C. Park, Y.I. Yeom, AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth, *Oncotarget* 7 (2016) 48155–48167.
- [39] T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G.Z. Chen, J. Xie, T.L. Gu, R.D. Polakiewicz, J.L. Roessel, T.J. Boggon, F.R. Khuri, D.G. Gilliland, L.C. Cantley, J. Kaufman, J. Chen, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth, *Sci. Signal* 2 (2009) ra73.
- [40] D. Anastasiou, G. Pouligiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen, G. Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, C.J. Thomas, M.G. Vander Heiden, L.C. Cantley, Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to antioxidant responses, *Science* 334 (6060) (2011) 1278–1283.
- [41] P. Presek, M. Reinacher, E. Eigenbrodt, Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus, *FEBS Lett.* 242 (1988) 194–198.
- [42] B.A. Ballif, G.R. Carey, S.R. Sunyaev, S.P. Gygi, Large-scale identification and evolution indexing of tyrosine phosphorylation sites from murine brain, *J. Proteome Res.* 7 (2008) 311–318.
- [43] J. Rush, A. Moritz, K.A. Lee, A. Guo, V.L. Goss, E.J. Spek, H. Zhang, X.M. Zha, R.D. Polakiewicz, M.J. Comb, Immunofluorescence profiling of tyrosine phosphorylation in cancer cells, *Nat. Biotechnol.* 23 (2005) 94–101.
- [44] P. Kachel, B. Trojanowicz, C. Sekulla, H. Prenzel, H. Dralle, C. Hoang-Vu, Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue, *BMC Cancer* 15 (2015) 140.
- [45] A. Betteaieb, J. Bakke, N. Nagata, K. Matsuo, Y. Xi, S. Liu, D. AbouBechara, R. Melhem, K. Stanhope, B. Cummings, J. Graham, A. Bremer, S. Zhang, C.A. Lyssiotis, Z.Y. Zhang, L.C. Cantley, P.J. Havel, F.G. Haj, Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation, *J. Biol. Chem.* 288 (2013) 17360–17371.
- [46] M. Gosalvez, L. Lopez-Alarcon, S. Garcia-Suarez, A. Montalvo, S. Weinhouse, Stimulation of tumor-cell respiration by inhibitors of pyruvate kinase, *Eur. J. Biochem.* 55 (1975) 315–321.
- [47] M. Gosalvez, J. Perez-Garcia, S. Weinhouse, Competition for ADP between pyruvate kinase and mitochondrial oxidative phosphorylation as a control mechanism in glycolysis, *Eur. J. Biochem.* 46 (1974) 133–140.
- [48] H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, L.C. Cantley, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, *Nature* 452 (2008) 230–233.
- [49] C. Chen, T. Wang, F. Wu, W. Huang, G. He, L. Ouyang, M. Xiang, C. Peng, Q. Jiang, Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity, *Drug Des. Devel. Ther.* 8 (2014) 1195–1210.
- [50] K.M. Parnell, J.M. Foulks, R.N. Nix, A. Clifford, J. Bullough, B. Luo, A. Senina, D. Vollmer, J. Liu, V. McCarthy, Y. Xu, M. Saunders, X.H. Liu, S. Pearce, K. Wright, M. O'Reilly, M.V. McCullar, K.K. Ho, S.B. Kanner, Pharmacologic activation of PKM2 slows lung tumor xenograft growth, *Mol. Cancer Ther.* 12 (2013) 1453–1460.
- [51] D. Anastasiou, Y. Yu, W.J. Israelsen, J.K. Jiang, M.B. Boxer, B.S. Hong, W. Tempel, S. Dimov, M. Shen, A. Jha, H. Yang, K.R. Mattaini, C.M. Metallo, B.P. Fiske, K.D. Courtney, S. Malstrom, T.M. Khan, C. Kung, A.P. Skoumbourdis, H. Veith, N. Southall, M.J. Walsh, K.R. Brimacombe, W. Leister, S.Y. Lunt, Z.R. Johnson, K.E. Yen, K. Kuni, S.M. Davidson, H.R. Christofk, C.P. Austin, J. Ingles, M.H. Harris, J.M. Asara, G. Stephanopoulos, F.G. Salituro, S. Jin, L. Dang, D.S. Auld, H.W. Park, L.C. Cantley, C.J. Thomas, M.G. Vander Heiden, Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis, *Nat. Chem. Biol.* 8 (2012) 839–847.
- [52] D. Auld, M. Shen, A.P. Skoumbourdis, J. Jiang, M. Boxer, N. Southall, J. Ingles, C. Thomas, Identification of activators for the M2 isoform of human pyruvate kinase, *Probe Reports from the NIH Molecular Libraries Program*, 2010.
- [53] M.B. Boxer, J.K. Jiang, M.G. Vander Heiden, M. Shen, A.P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C.P. Austin, H.W. Park, J. Ingles, L.C. Cantley, D.S. Auld, C.J. Thomas, Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase, *J. Med. Chem.* 53 (2010) 1048–1055.
- [54] J.K. Jiang, M.B. Boxer, M.G. Vander Heiden, M. Shen, A.P. Skoumbourdis, N. Southall, H. Veith, W. Leister, C.P. Austin, H.W. Park, J. Ingles, L.C. Cantley, D.S. Auld, C.J. Thomas, Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase, *Bioorg. Med. Chem. Lett.* 20 (2010) 3387–3393.
- [55] M.J. Walsh, K.R. Brimacombe, D. Anastasiou, Y. Yu, W.J. Israelsen, B.S. Hong, W. Tempel, S. Dimov, H. Veith, H. Yang, C. Kung, K.E. Yen, L. Dang, F. Salituro, D.S. Auld, H.W. Park, M.G. Vander Heiden, C.J. Thomas, M. Shen, M.B. Boxer, ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model, (2010).
- [56] M.B. Boxer, J. Jiang, M.G. Vander Heiden, M. Shen, H. Veith, L.C. Cantley, C.J. Thomas, Identification of activators for the M2 isoform of human pyruvate kinase Version 3, (2010).
- [57] W. Li, J. Liu, Y. Zhao, PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells, *Mol. Carcinog.* 53 (2014) 403–412.
- [58] J. Chen, Z. Jiang, B. Wang, Y. Wang, X. Hu, Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2, *Cancer Lett.* 316 (2) (2011) 204–210.
- [59] J. Chen, J. Xie, Z. Jiang, B. Wang, Y. Wang, X. Hu, Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2, *Oncogene* 30 (2011) 4297–4306.
- [60] M.G. Vander Heiden, H.R. Christofk, E. Schuman, A.O. Subtelny, H. Sharfi, E.E. Harlow, J. Xian, L.C. Cantley, Identification of small molecule inhibitors of pyruvate kinase M2, *Biochem. Pharmacol.* 79 (2010) 1118–1124.
- [61] R. Li, X. Ning, S. Zhou, Z. Lin, X. Wu, H. Chen, X. Bai, X. Wang, Z. Ge, R. Li, Y. Yin, Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators, *Eur. J. Med. Chem.* 143 (2018) 48–65.
- [62] D.J. Kim, Y.S. Park, N.D. Kim, S.H. Min, Y.M. You, Y. Jung, H. Koo, H. Noh, J.A. Kim, K.C. Park, Y.I. Yeom, A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia, *Mol. Cell* 38 (2015) 373–379.
- [63] E. Aslan, S. Adem, In vitro effects of some flavones on human pyruvate kinase isoenzyme M2, *J. Biochem. Mol. Toxicol.* 29 (2015) 109–113.
- [64] Y. Zhang, B. Liu, X. Wu, R. Li, X. Ning, Y. Liu, Z. Liu, Z. Ge, R. Li, Y. Yin, New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds, *Bioorg. Med. Chem.* 23 (2015) 4815–4823.
- [65] L. You, H. Zhu, C. Wang, F. Wang, Y. Li, Y. Li, Y. Wang, B. He, Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2, *Bioorg. Med. Chem. Lett.* 27 (2017) 5404–5408.
- [66] X. H. Ning, R. Qi, Y. Li, M.A. Jin, Y. McNutt, Yin, Synthesis and antitumor activity of novel 2,3-dithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase m2 isoform, *J. Enzyme Inhib. Med. Chem.* 33 (2017) 126–129.
- [67] J. Chen, Z. Jiang, B. Wang, Y. Wang, X. Hu, Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2, *Cancer Lett.* 316 (2012) 204–210.
- [68] G.A. Spoden, S. Mazurek, D. Morandell, N. Bacher, M.J. Ausserlechner, P. Jansen-Durr, E. Eigenbrodt, W. Zwerschke, Isozyme-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation, *Int. J. Cancer* 123 (2008) 312–321.
- [69] F.R. Garcia-Gonzalo, C. Cruz, P. Munoz, S. Mazurek, E. Eigenbrodt, F. Ventura, R. Bartrons, J.L. Rosa, Interaction between HERC1 and M2-type pyruvate kinase, *FEBS Lett.* 539 (2003) 78–84.
- [70] W. Luo, H. Hu, R. Chang, J. Zhong, M. Knabel, R. O'Meally, R.N. Cole, A. Pandey, G.L. Semenza, Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1, *Cell* 145 (2011) 732–744.
- [71] S. Mazurek, W. Zwerschke, P. Jansen-Durr, E. Eigenbrodt, Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7, *Oncogene* 20 (2001) 6891–6898.
- [72] L. Huang, Z. Yu, T. Zhang, X. Zhao, G. Huang, HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells, *PLoS One* 9 (2014) e92949.
- [73] H.J. Wang, Y.J. Hsieh, W.C. Cheng, C.P. Lin, Y.S. Lin, S.F. Yang, C.C. Chen, Y. Izumiya, J.S. Yu, H.J. Kung, W.C. Wang, JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1 α -mediated glucose metabolism, *Proc. Natl. Acad. Sci. U. S. A.* 111 (2014) 279–284.
- [74] J.N. Boeckel, A. Derlet, S.F. Glaser, A. Luczak, T. Lucas, A.W. Heumuller, M. Kruger, C.M. Zehendner, D. Kaluza, A. Daddaballapur, K. Ohtani, K. Treguer, S. Dimmeler, JMJD8 regulates angiogenic sprouting and cellular metabolism by interacting with pyruvate kinase M2 in endothelial cells, *Arterioscler. Thromb. Vasc. Biol.* 36 (2016) 1425–1433.
- [75] K.H. Ibsen, Interrelationships and functions of the pyruvate kinase isozymes and their variant forms: a review, *Cancer Res.* 37 (1977) 341–353.
- [76] C.W. van Veelen, H. Verbiest, A.M. Vlugg, G. Rijkse, G.E. Staal, Isozymes of pyruvate kinase from human brain, meningiomas, and malignant gliomas, *Cancer Res.* 38 (1978) 4681–4687.
- [77] H. Guderley, P.W. Hochachka, Catalytic and regulatory properties of muscle pyruvate kinase from Cancer magister, *J. Exp. Zool.* 212 (1980) 461–469.
- [78] L. Lopez-Alarcon, P. Ruiz, M. Gosalvez, Quantitative determination of the degree of differentiation of mammary tumors by pyruvate kinase kinetic analysis, *Cancer Res.* 41 (1981) 2019–2020.
- [79] F. Schapira, Resurgence of fetal isozymes in cancer: study of aldolase, pyruvate kinase, lactic dehydrogenase, and beta-hexosaminidase, *Isozymes Curr. Top Biol. Med. Res.* 5 (1981) 27–75.
- [80] D. Cottreau, M.F. Rousseau-Merck, C. Nezelof, A. Kahn, Pyruvate kinase and phosphofructokinase isozymes in childhood cancers, *Pediatr. Res.* 16 (1982) 199–202.
- [81] P. Gali, L. Hartmann, Immunocytochemical study of pyruvate kinase isoenzymes in normal and pathologic human liver, *Liver* 2 (1982) 236–243.
- [82] K.H. Ibsen, R.A. Orlando, K.N. Garratt, A.M. Hernandez, S. Giorlando, G. Nungaray, Expression of multimolecular forms of pyruvate kinase in normal, benign, and malignant human breast tissue, *Cancer Res.* 42 (1982) 888–892.
- [83] S. Yanagi, H. Tsuda, M. Sakamoto, Y. Ninomiya, N. Ito, Evaluation of a histologic classification of mouse liver tumors based on pyruvate kinase isozymes and status

- of host lipids, *J. Natl. Cancer Inst.* 73 (1984) 1311–1317.
- [84] F.A. Farina, J.B. Shattin, H.P. Morris, S. Weinhouse, Isozymes of pyruvate kinase in liver and hepatomas of the rat, *Cancer Res.* 34 (1974) 1439–1446.
- [85] H. Wu, P. Yang, W. Hu, Y. Wang, Y. Lu, L. Zhang, Y. Fan, H. Xiao, Z. Li, Overexpression of PKM2 promotes mitochondrial fusion through attenuated p53 stability, *Oncotarget* 7 (2016) 78069–78082.
- [86] F. Ji, B. Guo, N. Wang, C. Zhong, L. Huang, Y. Huang, L. Wei, M. Su, Y. Jiang, Q. Jin, Y. Liu, Z. Zhang, J. Yang, T. Chen, Pyruvate kinase M2 interacts with mammalian sterile 20-like kinase 1 and inhibits tamoxifen-induced apoptosis in human breast cancer cells, *Tumour Biol.* 39 (2017) (1010428317692251).
- [87] K.H. Ibsen, E. Krueger, Distribution of pyruvate kinase isozymes among rat organs, *Arch. Biochem. Biophys.* 157 (1973) 509–513.
- [88] E.R. Hall, G.L. Cottam, Isozymes of pyruvate kinase in vertebrates: their physical, chemical, kinetic and immunological properties, *Int. J. BioChemiPhysics* 9 (1978) 785–793.
- [89] J.B. Blair, Regulatory properties of hepatic pyruvate kinase, in: C.M. Venezia (Ed.), *The Regulation of Carbohydrate Formation and Utilization in Mammals*, University Park Press, Place Published, 1980, pp. 121–151.
- [90] A. Kahn, J. Marie, Pyruvate kinases from human erythrocytes and liver, *Methods Enzymol.* 90 (1982) 131–140.
- [91] G. Valentini, L.R. Chiarelli, R. Fortin, M. Dolzan, A. Galizzi, D.J. Abraham, C. Wang, P. Bianchi, A. Zanella, A. Mattevi, Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia, *J. Biol. Chem.* 277 (2002) 23807–23814.
- [92] G.B. van den Berg, T.J. van Berkel, J.F. Koster, Identification of L-type pyruvate kinase as a major phosphorylation site of endogenous cyclic AMP-dependent protein kinase in rat liver soluble fraction, *FEBS Lett.* 101 (1979) 289–294.
- [93] J. Marie, H. Buc, M.P. Simon, A. Kahn, Phosphorylation of human erythrocyte pyruvate kinase by soluble cyclic-AMP-dependent protein kinases. Comparison with human liver L-type enzyme, *Eur. J. Biochem.* 108 (1980) 251–260.
- [94] G.A. Spoden, D. Morandell, D. Ehehalt, M. Fiedler, P. Jansen-Durr, M. Hermann, W. Zwerschke, The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2, *J. Cell. Biochem.* 107 (2009) 293–302.
- [95] Y. Xiangyun, N. Xiaomin, G. Linping, X. Yunhua, L. Ziming, Y. Yongfeng, C. Zhiwei, L. Shun, Desuccinylation site of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth, *Oncotarget* 8 (2017) 6984–6993.
- [96] T. Noguchi, H. Inoue, T. Tanaka, The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing, *J. Biol. Chem.* 261 (1986) 13807–13812.
- [97] A.J. Hance, J. Lee, M. Feitelson, The M1 and M2 isozymes of pyruvate kinase are the products of the same gene, *Biochem. Biophys. Res. Commun.* 106 (1982) 492–499.
- [98] R. Viana, P. Lujan, P. Sanz, The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2, *BMC Biochem.* 16 (2015) 24.
- [99] K. Liu, F. Li, H. Han, Y. Chen, Z. Mao, J. Luo, Y. Zhao, B. Zheng, W. Gu, W. Zhao, Parkin Regulates the Activity of Pyruvate Kinase M2, *J. Biol. Chem.* 291 (2016) 10307–10317.
- [100] K. Imamura, T. Tanaka, Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies, *J. Biochem (Tokyo)* 71 (1972) 1043–1051.
- [101] K. Imamura, T. Tanaka, Pyruvate kinase isozymes from rat, *Methods Enzymol.* 90 (Pt E) (1982) 150–165.
- [102] Z. Lu, T. Hunter, Prolyl isomerase Pin1 in cancer, *Cell Res.* 24 (2014) 1033–1049.
- [103] J.R. Elbers, J.A. van Unnik, G. Rijkse, B.A. van Oirschot, P.J. Roholl, J. Oosting, G.E. Staal, Pyruvate kinase activity and isozyme composition in normal fibrous tissue and fibroblastic proliferations, *Cancer* 67 (1991) 2552–2559.
- [104] C. Guiguen-Guillouzo, M.F. Szajnert, J. Marie, D. Delain, F. Schapira, Differentiation in vivo and in vitro of pyruvate kinase isozymes in rat muscle, *Biochimie* 59 (1977) 65–71.
- [105] K. Harada, S. Saheki, K. Wada, T. Tanaka, Purification of four pyruvate kinase isozymes of rats by affinity elution chromatography, *Biochim. Biophys. Acta* 524 (1978) 327–339.
- [106] K. Imamura, K. Taniuchi, T. Tanaka, Multimolecular forms of pyruvate kinase. II. Purification of M 2 -type pyruvate kinase from Yoshida ascites hepatoma 130 cells and comparative studies on the enzymological and immunological properties of the three types of pyruvate kinases, L, M1, and M2, *J. Biochem. (Tokyo)* 72 (1972) 1001–1015.
- [107] J. Lee, H.K. Kim, Y.M. Han, J. Kim, Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription, *Int. J. Biochem. Cell Biol.* 40 (2008) 1043–1054.
- [108] Y. Li, Y. Chang, L. Zhang, Q. Feng, Z. Liu, Y. Zhang, J. Zuo, Y. Meng, F. Fang, High glucose upregulates pantothenate kinase 4 (PanK4) and thus affects M2-type pyruvate kinase (Pkm2), *Mol. Cell. Biochem.* 277 (2005) 117–125.
- [109] N. Chen, O. Rinner, D. Czernik, K.J. Nytko, D. Zheng, D.P. Stiehl, N. Zamboni, M. Gstaiger, C. Frei, The oxygen sensor PHD3 limits glycolysis under hypoxia via direct binding to pyruvate kinase, *Cell Res.* 21 (2011) 983–986.
- [110] H.R. Christofk, M.G. Vander Heiden, N. Wu, J.M. Asara, L.C. Cantley, Pyruvate kinase M2 is a phosphotyrosine-binding protein, *Nature* 452 (2008) 181–186.
- [111] H.J. Hacker, P. Steinberg, P. Bannasch, Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet, *Carcinogenesis* 19 (1998) 99–107.
- [112] L.G. Boros, M. Cascante, W.N. Lee, Metabolic profiling of cell growth and death in cancer: applications in drug discovery, *Drug Discov. Today* 7 (2002) 364–372.
- [113] A.S. Ahmed, T. Dew, F.G. Lawton, A.J. Papadopoulos, O. Devaja, K.S. Raju, R.A. Sherwood, M2-PK as a novel marker in ovarian cancer. A prospective cohort study, *Eur. J. Gynaecol. Oncol.* 28 (2007) 83–88.
- [114] J. Schneider, Tumor markers in detection of lung cancer, *Adv. Clin. Chem.* 42 (2006) 1–41.
- [115] S. Ugurel, N. Bell, A. Sucker, A. Zimpfer, W. Rittgen, D. Schadendorf, Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma, *Int. J. Cancer* 117 (2005) 825–830.
- [116] N. Shimada, T. Shinagawa, S. Ishii, Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein, *Genes Cells* 13 (2008) 245–254.
- [117] B. Varghese, G. Swaminathan, A. Plotnikov, C. Tzimas, N. Yang, H. Rui, S.Y. Fuchs, Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation, *Mol. Endocrinol.* 24 (2010) 2356–2365.
- [118] L. Xia, X.R. Wang, X.L. Wang, S.H. Liu, X.W. Ding, G.Q. Chen, Y. Lu, A novel role for pyruvate kinase M2 as a corepressor for P53 during the DNA damage response in human tumor cells, *J. Biol. Chem.* 291 (2016) 26138–26150.
- [119] Z. Zhang, Q. Liu, Y. Che, X. Yuan, L. Dai, B. Zeng, G. Jiao, Y. Zhang, X. Wu, Y. Yu, Y. Zhang, R. Yang, Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3, *Cancer Res.* 70 (2010) 89–98.
- [120] X. Zhao, L. Zhao, H. Yang, J. Li, X. Min, F. Yang, J. Liu, G. Huang, Pyruvate kinase M2 interacts with nuclear sterol regulatory element-binding protein 1a and thereby activates lipogenesis and cell proliferation in hepatocellular carcinoma, *J. Biol. Chem.* 293 (2018) 6623–6634.
- [121] M. Board, S. Humm, E.A. Newsholme, Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells, *Biochem. J.* 265 (1990) 503–509.
- [122] R. Weinberger, B. Appel, A. Stein, Y. Metz, A. Neheman, M. Barak, The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma, *Eur. J. Cancer Care (Engl)* 16 (2007) 333–337.
- [123] K.H. Ibsen, R.H.-C. Chiu, H.R. Park, D.A. Sanders, S. Roy, K.N. Garratt, M.K. Mueller, Purification and properties of mouse pyruvate kinases K and M and of a modified K subunit, *Biochemistry* 20 (1981) 1497–1506.
- [124] R. Williams, T. Holyoak, G. McDonald, C. Gui, A.W. Fenton, Differentiating a ligand's chemical requirements for allosteric interactions from those for protein binding. phenylalanine inhibition of pyruvate kinase, *Biochemistry* 45 (2006) 5421–5429.
- [125] A. Hamabe, M. Konno, N. Tanuma, H. Shima, K. Tsunekuni, K. Kawamoto, N. Nishida, J. Koseki, K. Mimori, N. Gotoh, H. Yamamoto, Y. Doki, M. Mori, H. Ishii, Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition, *Proc. Natl. Acad. Sci. U. S. A.* 111 (2014) 15526–15531.
- [126] Z. Chen, Z. Wang, W. Guo, Z. Zhang, F. Zhao, Y. Zhao, D. Jia, J. Ding, H. Wang, M. Yao, X. He, TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma, *Oncogene* 34 (2015) 3946–3956.
- [127] F. Liang, Q. Li, X. Li, Z. Li, Z. Gong, H. Deng, B. Xiang, M. Zhou, X. Li, G. Li, Z. Zeng, W. Xiong, TSC2D2 interacts with PKM2 and inhibits cell growth in colorectal cancer, *Int. J. Oncol.* 49 (2016) 1046–1056.
- [128] M. Guminska, J. Ignacak, Electrophoretic pattern of cytosolic pyruvate kinase fractions A and B (type L and M2) from normal rat liver and Morris hepatoma 7777, *Biochim. Biophys. Acta* 1292 (1996) 99–105.
- [129] M. Guminska, J. Ignacak, T. Kedryna, M.B. Stachurska, Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells, *Acta Biochim. Pol.* 44 (1997) 711–724.
- [130] M. Guminska, M.B. Stachurska, J. Ignacak, Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour, Morris hepatoma 7777 and normal mouse and rat livers, *Biochim. Biophys. Acta* 966 (1988) 207–213.
- [131] J. Ignacak, M. Guminska, Comparison of pyruvate kinase variants from rat liver and Morris hepatoma 7777, obtained by an affinity chromatography on blue sepharose CL-6B, *Acta Biochim. Pol.* 40 (1993) 261–267.
- [132] J. Ignacak, M. Guminska, N-acetylneuraminic acid, phosphate and thiol groups of pyruvate kinase isoenzymes from Morris hepatoma 7777 and normal rat liver, *Acta Biochim. Pol.* 44 (1997) 201–208.
- [133] J. Ignacak, M. Guminska, J. Steczko, Amino-acid composition of pyruvate kinase M2 isoenzyme variants from rat liver and Morris hepatoma 7777, *Acta Biochim. Pol.* 45 (1998) 775–780.
- [134] J. Ignacak, M.B. Stachurska, The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells, *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* 134 (2003) 425–433.
- [135] E. Eigenbrodt, S. Leib, W. Kramer, R.R. Friis, W. Schoner, Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors, *Biomed Biochim Acta* 42 (1983) S278–S282.
- [136] K.H. Ibsen, J.R. Basabe, T.P. Lopez, Extraction of a factor from Ehrlich ascites tumor cells that increases the activity of the fetal isozyme of pyruvate kinase in mouse liver, *Cancer Res.* 35 (1975) 180–188.
- [137] J.L. Ngo, H. Chute, D.A. Sanders, R.A. Orlando, K.H. Ibsen, Regulation of pyruvate kinase expression and growth in mastocytoma cells. I. Initial observations, *Exp. Cell Res.* 149 (1983) 565–575.
- [138] T. Kedryna, M. Guminska, E. Marchut, Pyruvate kinase from cytosolic fractions of the Ehrlich ascites tumour, normal mouse liver and skeletal muscle, *Biochim. Biophys. Acta* 1039 (1990) 130–133.
- [139] E. Marchut, M. Guminska, T. Kedryna, C. Radzikowski, H. Kusnierczyk, A pyruvate kinase variant in different mouse transplanted tumors, *Experientia* 44 (1988) 25–27.
- [140] M. Guminska, M.B. Stachurska, B. Christensen, V. Tromholt, J. Kieler, C. Radzikowski, D. Dus, Pyruvate kinase inhibited by L-cysteine as a marker of

- tumorigenic human urothelial cell lines, *Experientia* 45 (1989) 571–574.
- [141] G. Weber, Carbohydrate metabolism in cancer cells and the molecular correlation concept, *Die Naturwissenschaften* 55 (1968) 418–429.
- [142] P.A. Weernink, G. Rijkse, E.M. Mascini, G.E. Staal, Phosphorylation of pyruvate kinase type K is restricted to the dimeric form, *Biochim. Biophys. Acta* 1121 (1992) 61–68.
- [143] M. Yuan, I.W. McNae, Y. Chen, E.A. Blackburn, M.A. Wear, P.A.M. Michels, L.A. Fothergill-Gilmore, T. Hupp, M.D. Walkinshaw, An allostatic mechanism for M2 pyruvate kinase as an amino-acid sensor, *Biochem. J.* 475 (2018) 1821–1837.
- [144] K. Ashizawa, M.C. Willingham, C.M. Liang, S.Y. Cheng, In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate, *J. Biol. Chem.* 266 (1991) 16842–16846.
- [145] E. Hofmann, B.I. Kurganov, W. Schellenberger, J. Schulz, G. Sparmann, K.W. Wenzel, G. Zimmermann, Association-dissociation behavior of erythrocyte phosphofructokinase and tumor pyruvate kinase, *Adv. Enzym. Regul.* 13 (1975) 247–277.
- [146] P.A. Oude Weernink, G. Rijkse, G.E. Staal, Phosphorylation of pyruvate kinase and glycolytic metabolism in three human glioma cell lines, *Tumour Biol.* 12 (1991) 339–352.
- [147] A.F.M. Gavriilidou, F.P. Holding, D. Mayer, J.E. Coyle, D.B. Veprintsev, R. Zenobi, Native Mass Spectrometry Gives Insight into the Allosteric Binding Mechanism of M2 Pyruvate Kinase to Fructose-1,6-Bisphosphate, *Biochemistry* 57 (2018) 1685–1689.
- [148] H.P. Morgan, F.J. O'Reilly, M.A. Wear, J.R. O'Neill, L.A. Fothergill-Gilmore, T. Hupp, M.D. Walkinshaw, M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 5881–5886.
- [149] J. Schulz, G. Sparmann, E. Hofmann, Alanine-mediated reversible inactivation of tumour pyruvate kinase caused by a tetramer-dimer transition, *FEBS Lett.* 50 (1975) 346–350.
- [150] G. Sparmann, J. Schulz, E. Hofmann, Effects of L-alanine and fructose (1,6-diphosphate) on pyruvate kinase from Ehrlich ascites tumour cells, *FEBS Lett.* 36 (1973) 305–308.
- [151] X. Gao, H. Wang, J.J. Yang, X. Liu, Z.R. Liu, Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase, *Mol. Cell* 45 (2012) 598–609.
- [152] R.G. Shulman, D.L. Rothman, The glycogen shunt maintains glycolytic homeostasis and the Warburg effect in cancer, *Trends Cancer* 3 (2017) 761–767.
- [153] W.N. Lee, P. Guo, S. Lim, S. Bassilian, S.T. Lee, J. Boren, M. Cascante, V.L. Go, L.G. Boros, Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment, *Br. J. Cancer* 91 (2004) 2094–2100.
- [154] D. Ma, J. Wang, Y. Zhao, W.N. Lee, J. Xiao, V.L. Go, Q. Wang, R.R. Recker, G.G. Xiao, Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells, *Pancreas* 41 (2012) 397–408.
- [155] S. Weinhouse, Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture, *Cancer Res.* 32 (1972) (2007-2016).
- [156] M. Tokunaga, K. Kami, S. Ozawa, J. Oguma, A. Kazuno, H. Miyachi, Y. Ohashi, M. Kusahara, M. Terashima, Metabolome analysis of esophageal cancer tissues using capillary electrophoresis-time-of-flight mass spectrometry, *Int. J. Oncol.* 52 (2018) 1947–1958.
- [157] P.A. Lazo, Amino acids and glucose utilization by different metabolic pathways in ascites-tumour cells, *Eur. J. Biochem.* 117 (1981) 19–25.
- [158] W. Grabon, D. Otto-Slusarczyk, A. Chrzanowska, M. Mielczarek-Putna, I. Joniec-Maciejak, K. Slabik, A. Baranczyk-Kuzma, Lactate formation in primary and metastatic colon cancer cells at hypoxia and normoxia, *Cell Biochem. Funct.* 34 (2016) 483–490.
- [159] E. Eigenbrodt, M. Reinacher, U. Scheefers-Borchel, H. Scheefers, R. Friis, Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells, *Crit. Rev. Oncog.* 3 (1992) 91–115.
- [160] W.L. McKeehan, Glycolysis, glutaminolysis and cell proliferation, *Cell Biol. Int. Rep.* 6 (1982) 635–650.
- [161] Z. Kovacevic, J.D. McGivan, Mitochondrial metabolism of glutamine and glutamate and its physiological significance, *Physiol. Rev.* 63 (1983) 547–605.
- [162] J. Perez-Escuredo, R.K. Dadhich, S. Dhup, A. Cacace, V.F. Wang, R.R. Hee, C.J. De Saedeleer, M. Sboarina, F. Rodriguez, M.J. Fontenille, L. Brisson, P.E. Porporato, P. Sonveaux, Lactate promotes glutamine uptake and metabolism in oxidative cancer cells, *Cell Cycle* 15 (2016) 72–83.
- [163] J.A. Maresperman, E. Shrago, Energy substrate utilization in freshly isolated morris hepatoma 7777 cells, *Cancer Res.* 48 (1988) 602–608.
- [164] L.J. Reitzer, B.M. Wice, D. Kennell, Evidence that glutamine, not sugar, is the major energy-source for cultured hela-cells, *J. Biol. Chem.* 254 (1979) 2669–2676.
- [165] O.H. Lowry, J.V. Passonneau, F.X. Hasselberger, D. Schulz, Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain, *J. Biol. Chem.* 239 (1964) 18–30.
- [166] D.C. Howse, T.H. Duffy, Control of the redox state of the pyridine nucleotides in the rat cerebral cortex. Effect of electroshock-induced seizures, *J. Neurochem.* 24 (1975) 935–940.
- [167] D. Sahu, Y. Lotan, B. Wittmann, B. Neri, D.E. Hansel, Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer, *Cancer Med.* 6 (2017) 2106–2120.
- [168] L. Willmann, M. Schlimpert, S. Halbach, T. Erbes, E. Stickeler, B. Kammerer, Metabolic profiling of breast cancer: Differences in central metabolism between subtypes of breast cancer cell lines, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 1000 (2015) 95–104.
- [169] A. Flores, S. Sandoval-Gonzalez, R. Takahashi, A. Krall, L. Sathe, L. Wei, C. Radu, J. Jolly, N. Graham, H.R. Christofk, W.E. Lowry, Increased lactate dehydrogenase activity is dispensable in squamous carcinoma cells of origin, *Nat. Commun.* 10 (2019) 91.
- [170] P. Wang, C. Sun, T. Zhu, Y. Xu, Structural insight into mechanisms for dynamic regulation of PKM2, *Protein Cell* 6 (2015) 275–287.
- [171] M.A. Steinmetz, W.C. Deal Jr., Metabolic control and structure of glycolytic enzymes. 3. Dissociation and subunit structure of rabbit muscle pyruvate kinase, *Biochemistry* 5 (1966) 1399–1405.
- [172] G.L. Cottam, P.F. Hollenberg, M.J. Coon, Subunit structure of rabbit muscle pyruvate kinase, *J. Biol. Chem.* 244 (1969) 1481–1486.
- [173] W. Doster, B. Hess, Reversible solvent denaturation of rabbit muscle pyruvate kinase, *Biochemistry* 20 (1981) 772–780.
- [174] F. Edwin, M.V. Jagannadham, Salt-induced folding of a rabbit muscle pyruvate kinase intermediate at alkaline pH, *J. Protein Chem.* 19 (2000) 361–371.
- [175] F.G. De Felice, V.C. Soares, S.T. Ferreira, Subunit dissociation and inactivation of pyruvate kinase by hydrostatic pressure oxidation of sulfhydryl groups and ligand effects on enzyme stability, *Eur. J. Biochem.* 266 (1999) 163–169.
- [176] T.G. Consler, J.C. Lee, Domain interaction in rabbit muscle pyruvate kinase. I. Effects of ligands on protein denaturation induced by guanidine hydrochloride, *J. Biol. Chem.* 263 (1988) 2787–2793.
- [177] R.H. Friesen, A.J. Chin, D.W. Ledman, J.C. Lee, Interfacial communications in recombinant rabbit kidney pyruvate kinase, *Biochemistry* 37 (1998) 2949–2960.
- [178] S. Mazurek, Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours, *Ernst Schering Foundation Symposium Proceedings*, 2008, pp. 99–124.
- [179] M. Yan, S. Chakravarthy, J.M. Tokuda, L. Pollack, G.D. Bowman, Y.S. Lee, Succinyl-5-aminoimidazole-4-carboxamide-1-ribose 5'-Phosphate (SAICAR) Activates Pyruvate Kinase Isoform M2 (PKM2) in Its Dimeric Form, *Biochemistry* 55 (2016) 4731–4736.
- [180] Y. Kumar, S. Mazurek, S. Yang, K. Failing, M. Winslet, B. Fuller, B.R. Davidson, In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines, *Tumour Biol.* 31 (2010) 69–77.
- [181] P.D. Hardt, S. Mazurek, M. Toepler, P. Schlierbach, R.G. Bretzel, E. Eigenbrodt, H.U. Kloer, Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer, *Br. J. Cancer* 91 (2004) 980–984.
- [182] W. Zhou, M. Capello, C. Fredolini, L. Piemonti, L.A. Liotta, F. Novelli, E.F. Petricoin, Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations, *J. Proteome Res.* 10 (2011) 1944–1952.
- [183] W. Zhou, M. Capello, C. Fredolini, L. Raccanich, L. Piemonti, L.A. Liotta, F. Novelli, E.F. Petricoin, Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells, *J. Proteome Res.* 11 (2012) 554–563.
- [184] C. Huang, Z. Huang, P. Bai, G. Luo, X. Zhao, X. Wang, Expression of pyruvate kinase M2 in human bladder cancer and its correlation with clinical parameters and prognosis, *Oncotargets Ther* 11 (2018) 2075–2082.
- [185] W. Lu, Y. Cao, Y. Zhang, S. Li, J. Gao, X.A. Wang, J. Mu, Y.P. Hu, L. Jiang, P. Dong, W. Gong, Y. Liu, Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer, *Sci. Rep.* 6 (2016) 26351.
- [186] S. Tian, P. Li, S. Sheng, X. Jin, Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer, *Oncol. Lett.* 15 (2018) 2211–2217.
- [187] C.C. Wong, S.L. Au, A.P. Tse, I.M. Xu, R.K. Lai, D.K. Chiu, L.L. Wei, D.N. Fan, F.H. Tsang, R.C. Lo, C.M. Wong, I.O. Ng, Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis, *PLoS One* 9 (2014) e115036.
- [188] K. Blumlein, N.M. Gruning, R.G. Feichtinger, H. Lehrach, B. Kofler, M. Ralsler, No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis, *Oncotarget* 2 (2011) 393–400.
- [189] C. Kobierzycki, B. Pula, B. Werynska, A. Piotrowska, B. Muszczyńska-Bernhard, P. Dziegiel, D. Rakus, The lack of evidence for correlation of pyruvate kinase M2 expression with tumor grade in non-small cell lung cancer, *Anticancer Res.* 34 (2014) 3811–3817.
- [190] A.N. Lau, W.J. Israelsen, J. Roper, M.J. Sinnamon, L. Georgeon, T.L. Dayton, A.L. Hillis, O.H. Yilmaz, D. Di Vizio, K.E. Hung, M.G. Vander Heiden, PKM2 is not required for colon cancer initiated by APC loss, *Cancer Metab.* 5 (2017) 10.
- [191] J. Mukherjee, J.J. Phillips, S. Zheng, J. Wiencke, S.M. Ronen, R.O. Pieper, Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma, *PLoS One* 8 (2013) e57610.
- [192] S.Y. Lunt, V. Muralidhar, A.M. Hosios, W.J. Israelsen, D.Y. Gui, L. Newhouse, M. Ogradzinski, V. Hecht, K. Xu, P.N. Acevedo, D.P. Hollern, G. Bellinger, T.L. Dayton, S. Christen, I. Elia, A.T. Dinh, G. Stephanopoulos, S.R. Manalis, M.B. Yaffe, E.R. Andrechek, S.M. Fendt, M.G. Vander Heiden, Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation, *Mol. Cell* 57 (2015) 95–107.
- [193] W.J. Israelsen, T.L. Dayton, S.M. Davidson, B.P. Fiske, A.M. Hosios, G. Bellinger, J. Li, Y. Yu, M. Sasaki, J.W. Horner, L.N. Burga, J. Xie, M.J. Jurczak, R.A. DePinho, C.B. Clish, T. Jacks, R.G. Kibbey, G.M. Wulf, D. Di Vizio, G.B. Mills, L.C. Cantley, M.G. Vander Heiden, PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells, *Cell* 155 (2013) 397–409.
- [194] M. Cortes-Cros, C. Hemmerlin, S. Ferretti, J. Zhang, J.S. Gounarides, H. Yin, A. Muller, A. Haberkorn, P. Chene, W.R. Sellers, F. Hofmann, M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 489–494.
- [195] M. Morita, T. Sato, M. Nomura, Y. Sakamoto, Y. Inoue, R. Tanaka, S. Ito, K. Kurosawa, K. Yamaguchi, Y. Sugiura, H. Takizaki, Y. Yamashita, R. Katakura,

- I. Sato, M. Kawai, Y. Okada, H. Watanabe, G. Kondoh, S. Matsumoto, A. Kishimoto, M. Obata, M. Matsumoto, T. Fukuhara, H. Motohashi, M. Suematsu, M. Komatsu, K.I. Nakayama, T. Watanabe, T. Soga, H. Shima, M. Maemondo, N. Tanuma, PKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growth, *Cancer Cell* 33 (2018) 355–367 e357.
- [196] J. Xie, C. Dai, X. Hu, Evidence that does not support pyruvate kinase M2 (PKM2)-catalyzed reaction as a rate-limiting step in cancer cell glycolysis, *J. Biol. Chem.* 291 (2016) 8987–8999.
- [197] A. Marin-Hernandez, S. Rodriguez-Enriquez, P.A. Vital-Gonzalez, F.L. Flores-Rodriguez, M. Macias-Silva, M. Sosa-Garrocho, R. Moreno-Sanchez, Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase, *FEBS J.* 273 (2006) 1975–1988.
- [198] G. Prakasam, M.A. Iqbal, R.N.K. Bamezai, S. Mazurek, Posttranslational modifications of pyruvate kinase M2: tweaks that benefit cancer, *Front. Oncol.* 8 (2018) 22.
- [199] T.G. Conslor, S.H. Woodard, J.C. Lee, Effects of primary sequence differences on the global structure and function of an enzyme: a study of pyruvate kinase isozymes, *Biochemistry* 28 (1989) 8756–8764.
- [200] Y. Ikeda, N. Taniguchi, T. Noguchi, Dominant negative role of the glutamic acid residue conserved in the pyruvate kinase M(1) isozyme in the heterotropic allosteric effect involving fructose-1,6-bisphosphate, *J. Biol. Chem.* 275 (2000) 9150–9156.
- [201] Y. Ikeda, T. Noguchi, Allosteric regulation of pyruvate kinase M2 isozyme involves a cysteine residue in the intersubunit contact, *J. Biol. Chem.* 273 (1998) 12227–12233.
- [202] Y. Ikeda, T. Tanaka, T. Noguchi, Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution, *J. Biol. Chem.* 272 (1997) 20495–20501.
- [203] D. Nakatsu, Y. Horiuchi, F. Kano, Y. Noguchi, T. Sugawara, I. Takamoto, N. Kubota, T. Kadowaki, M. Murata, L-cysteine reversibly inhibits glucose-induced biphasic insulin secretion and ATP production by inactivating PKM2, *Proc. Natl. Acad. Sci. U. S. A.* 112 (2015) E1067–E1076.
- [204] B. Chaneton, P. Hillmann, L. Zheng, A.C.L. Martin, O.D.K. Maddocks, A. Chokkathukalam, J.E. Coyle, A. Jankevics, F.P. Holding, K.H. Vousden, C. Frezza, M. O'Reilly, E. Gottlieb, Serine is a natural ligand and allosteric activator of pyruvate kinase M2, *Nature* 491 (2012) 458–462.
- [205] J. Ye, A. Mancuso, X. Tong, P.S. Ward, J. Fan, J.D. Rabinowitz, C.B. Thompson, Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation, *Proc. Natl. Acad. Sci. U. S. A.* 109 (2012) 6904–6909.
- [206] M. Gosalvez, S. Garcia-Suarez, L. Lopez-Alarcon, Metabolic control of glycolysis in normal and tumor permeabilized cells, *Cancer Res.* 38 (1978) 142–148.
- [207] K.E. Keller, Z.M. Doctor, Z.W. Dwyer, Y.S. Lee, SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells, *Mol. Cell* 53 (2014) 700–709.
- [208] R.L. Veech, J.W. Lawson, N.W. Cornell, H.A. Krebs, Cytosolic phosphorylation potential, *J. Biol. Chem.* 254 (1979) 6538–6547.
- [209] A.P. Halestrap, C. Brenner, The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death, *Curr. Med. Chem.* 10 (2003) 1507–1525.
- [210] E.N. Maldonado, D.N. DeHart, J. Patnaik, S.C. Klatt, M.B. Gooz, J.J. Lemasters, ATP/ADP turnover and import of glycolytic ATP into mitochondria in cancer cells is independent of the adenine nucleotide translocator, *J. Biol. Chem.* 291 (2016) 19642–19650.
- [211] D.N. DeHart, J.J. Lemasters, E.N. Maldonado, Erastin-like anti-warburg agents prevent mitochondrial depolarization induced by free tubulin and decrease lactate formation in cancer cells, *SLAS Discov* 23 (2018) 23–33.
- [212] E.A. Newsholme, M. Board, Application of metabolic-control logic to fuel utilization and its significance in tumor cells, *Adv. Enzym. Regul.* 31 (1991) 225–246.
- [213] A.K. Groen, C.W. van Roermund, R.C. Vervoorn, J.M. Tager, Control of gluconeogenesis in rat liver cells. Flux control coefficients of the enzymes in the gluconeogenic pathway in the absence and presence of glucagon, *Biochem. J.* 237 (1986) 379–389.
- [214] J.J. Hornberg, F.J. Bruggeman, B.M. Bakker, H.V. Westerhoff, Metabolic control analysis to identify optimal drug targets, *Prog. Drug Res.* 64 (2007) 173–189.
- [215] A. Hennipman, B.A. van Oirschot, J. Smits, G. Rijksen, G.E. Staal, Heterogeneity of glycolytic enzyme activity and isozyme composition of pyruvate kinase in breast cancer, *Tumour Biol.* 9 (1988) 178–189.
- [216] A. Marin-Hernandez, J.C. Gallardo-Perez, S.J. Ralph, S. Rodriguez-Enriquez, R. Moreno-Sanchez, HIF-1 α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms, *Mini-Rev. Med. Chem.* 9 (2009) 1084–1101.
- [217] K.D. Courtney, D. Bezwada, T. Mashimo, K. Pichumani, V. Vemireddy, A.M. Funk, J. Wimberly, S.S. McNeil, P. Kapur, Y. Lotan, V. Margulis, J.A. Cadeddu, I. Pedrosa, R.J. DeBerardinis, C.R. Malloy, R.M. Bachoo, E.A. Maher, Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo, *Cell Metab.* 28 (5) (2018) 793–800.
- [218] M.T. Snaebjornsson, A. Schulze, Non-canonical functions of enzymes facilitate cross-talk between cell metabolic and regulatory pathways, *Exp. Mol. Med.* 50 (2018) 34.
- [219] M.G. Vander Heiden, J.W. Locasale, K.D. Swanson, H. Sharfi, G.J. Heffron, D. Amador-Noguez, H.R. Christofk, G. Wagner, J.D. Rabinowitz, J.M. Asara, L.C. Cantley, Evidence for an alternative glycolytic pathway in rapidly proliferating cells, *Science* 329 (2010) 1492–1499.
- [220] C. Diaz-Jullien, D. Moreira, C.S. Sarandeses, G. Covelo, P. Barbeito, M. Freire, The M2-type isoenzyme of pyruvate kinase phosphorylates prothymosin alpha in proliferating lymphocytes, *Biochim. Biophys. Acta* 1814 (2011) 355–365.
- [221] Y. Jiang, Y. Wang, T. Wang, D.H. Hawke, Y. Zheng, X. Li, Q. Zhou, S. Majumder, E. Bi, D.X. Liu, S. Huang, Z. Lu, PKM2 phosphorylates MLC2 and regulates cyto-kinesis of tumour cells, *Nat. Commun.* 5 (2014) 5566.
- [222] W. Yang, Y. Xia, D. Hawke, X. Li, J. Liang, D. Xing, K. Aldape, T. Hunter, W.K. Alfred Yung, Z. Lu, PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis, *Cell* 150 (2012) 685–696.
- [223] T.Y. Cheng, Y.C. Yang, H.P. Wang, Y.W. Tien, C.T. Shun, H.Y. Huang, M. Hsiao, K.T. Hua, Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein, *Oncogene* 37 (2018) 1730–1742.
- [224] Y. Wei, D. Wang, F. Jin, Z. Bian, L. Li, H. Liang, M. Li, L. Shi, C. Pan, D. Zhu, X. Chen, G. Hu, Y. Liu, C.Y. Zhang, K. Zen, Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23, *Nat. Commun.* 8 (2017) 14041.
- [225] X. Gao, H. Wang, J.J. Yang, J. Chen, J. Jie, L. Li, Y. Zhang, Z.R. Liu, Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals, *J. Biol. Chem.* 288 (2013) 15971–15979.
- [226] C.L. He, Y.Y. Bian, Y. Xue, Z.X. Liu, K.Q. Zhou, C.F. Yao, Y. Lin, H.F. Zou, F.X. Luo, P.Y. Qu, J.Y. Zhao, M.L. Ye, S.M. Zhao, W. Xu, Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1, *Sci. Rep.* 6 (2016) 21524.
- [227] L. Xia, K. Qin, X.R. Wang, X.L. Wang, A.W. Zhou, G.Q. Chen, Y. Lu, Pyruvate kinase M2 phosphorylates H2AX and promotes genomic instability in human tumor cells, *Oncotarget* 8 (2017) 109120–109134.
- [228] Y. Jiang, X. Li, W. Yang, D.H. Hawke, Y. Zheng, Y. Xia, K. Aldape, C. Wei, F. Guo, Y. Chen, Z. Lu, PKM2 regulates chromosome segregation and mitosis progression of tumor cells, *Mol. Cell* 53 (2014) 75–87.
- [229] J. Liang, R. Cao, X. Wang, Y. Zhang, P. Wang, H. Gao, C. Li, F. Yang, R. Zeng, P. Wei, D. Li, W. Li, W. Yang, Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2, *Cell Res.* 27 (2017) 329–351.
- [230] A. Stetak, R. Veress, J. Ovadi, P. Csermely, G. Keri, A. Ullrich, Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death, *Cancer Res.* 67 (2007) 1602–1608.
- [231] A. Hoshino, J.A. Hirst, H. Fujii, Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase, *J. Biol. Chem.* 282 (2007) 17706–17711.
- [232] E. Giannoni, M.L. Taddei, A. Morandi, G. Comito, M. Calvani, F. Bianchini, B. Richiichi, G. Raugeri, N. Wong, D. Tang, P. Chiarugi, Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread, *Oncotarget* 6 (2015) 24061–24074.
- [233] Q. Li, D. Zhang, X. Chen, L. He, T. Li, X. Xu, M. Li, Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer, *Sci. Rep.* 5 (2015) 16082.
- [234] J. Zhang, G. Feng, G. Bao, G. Xu, Y. Sun, W. Li, L. Wang, J. Chen, H. Jin, Z. Cui, Nuclear translocation of PKM2 modulates astrocyte proliferation via p27 and -catenin pathway after spinal cord injury, *Cell Cycle* 14 (2015) 2609–2618.
- [235] F. Wang, K. Wang, W. Xu, S. Zhao, D. Ye, Y. Wang, Y. Xu, L. Zhou, Y. Chu, C. Zhang, X. Qin, P. Yang, H. Yu, SIRT5 desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1 β production and to prevent DSS-induced colitis in mice, *Cell Rep.* 19 (2017) 2331–2344.
- [236] S. Li, S.K. Swanson, M. Gogol, L. Florens, M.P. Washburn, J.L. Workman, T. Suganuma, Serine and SAM responsive complex SESAME regulates histone modification crosstalk by sensing cellular metabolism, *Mol. Cell* 60 (2015) 408–421.
- [237] M.D. Jeyasingham, G.M. Carlson, Evaluation of phosphoenolpyruvate as a phosphoryl group donor for phosphoproteins in skeletal muscle, *Arch. Biochem. Biophys.* 357 (1998) 285–292.
- [238] R.L. Mattoo, E.B. Waygood, R.L. Khandelwal, Activation of phosphoenolpyruvate-dependent protein kinase by cytidine 5'-triphosphate in rat skeletal muscle, *FEBS Lett.* 165 (1984) 117–120.
- [239] S. Ueda, S. Sakasegawa, H. Atomi, Development of an enzymatic cycling method using pyruvate kinase for assaying pyruvate or phosphoenolpyruvate, *Curr. Biotechnol.* 7 (2018) 125–131.
- [240] A.M. Hosios, B.P. Fiske, D.Y. Gui, M.G. Vander Heiden, Lack of evidence for PKM2 protein kinase activity, *Mol. Cell* 59 (2015) 850–857.
- [241] H. Wu, Z. Li, Y. Wang, P. Yang, Z. Li, H. Li, C. Wu, MiR-106b-mediated Mfn2 suppression is critical for PKM2 induced mitochondrial fusion, *Am. J. Cancer Res.* 6 (2016) 2221–2234.
- [242] L. Li, Y. Zhang, J. Qiao, J.J. Yang, Z.R. Liu, Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis, *J. Biol. Chem.* 289 (2014) 25812–25821.
- [243] M.C. Hsu, W.C. Hung, H. Yamaguchi, S.O. Lim, H.W. Liao, C.H. Tsai, M.C. Hung, Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway, *Am. J. Cancer Res.* 6 (2016) 628–638.
- [244] Y. Zhang, L. Li, Y. Liu, Z.R. Liu, PKM2 released by neutrophils at wound site facilitates early wound healing by promoting angiogenesis, *Wound Repair Regen.* 24 (2016) 328–336.
- [245] S. Gehrig, J.A. Macpherson, P.C. Driscoll, A. Symon, S.R. Martin, J.I. MacRae, J. Kleinjung, F. Fraternali, D. Anastasiou, An engineered photoswitchable mammalian pyruvate kinase, *FEBS J.* 284 (2017) 2955–2980.
- [246] X. Chen, Y. Qian, S. Wu, The Warburg effect: evolving interpretations of an established concept, *Free Radic. Biol. Med.* 79 (2015) 253–263.
- [247] L. Gao, R. Mejias, M. Echevarria, J. Lopez-Barneo, Induction of the glucose-6-phosphate dehydrogenase gene expression by chronic hypoxia in PC12 cells, *FEBS Lett.* 569 (2004) 256–260.
- [248] J.W. Locasale, A.R. Grassian, T. Melman, C.A. Lyssiotis, K.R. Mattaini, A.J. Bass,

- G. Heffron, C.M. Metallo, T. Muranen, H. Sharfi, A.T. Sasaki, D. Anastasiou, E. Mullarky, N.I. Vokes, M. Sasaki, R. Beroukhir, G. Stephanopoulos, A.H. Ligon, M. Meyerson, A.L. Richardson, L. Chin, G. Wagner, J.M. Asara, J.S. Brugge, L.C. Cantley, M.G. Vander Heiden, Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis, *Nat. Genet.* 43 (2011) 869–874.
- [249] B. Altenberg, K.O. Greulich, Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes, *Genomics* 84 (2004) 1014–1020.
- [250] J.W. Kim, I. Tchernyshyov, G.L. Semenza, C.V. Dang, HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia, *Cell Metab.* 3 (2006) 177–185.
- [251] S. Weinhouse, The Warburg hypothesis fifty years later, *Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol.* 87 (1976) 115–126.
- [252] J.D. Dombrackas, B.D. Santarsiero, A.D. Mesecar, Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis, *Biochemistry* 44 (2005) 9417–9429.
- [253] K.H. Ibsen, P. Trippet, Effects of amino acids on the kinetic properties of three noninterconvertible rat pyruvate kinases, *Arch. Biochem. Biophys.* 163 (1974) 570–580.
- [254] A.W. Fenton, M. Hutchinson, The pH dependence of the allosteric response of human liver pyruvate kinase to fructose-1,6-bisphosphate, ATP, and alanine, *Arch Biochem Biophys* 484 (2009) 16–23.
- [255] A.W. Fenton, A.Y. Alontaga, The impact of ions on allosteric functions in human liver pyruvate kinase, *Methods Enzymol.* 466 (2009) 83–107.
- [256] M.V. Shirmanova, I.N. Druzhkova, M.M. Lukina, M.E. Matlashov, V.V. Belousov, L.B. Snopova, N.N. Prodanetz, V.V. Dudenkova, S.A. Lukyanov, E.V. Zagaynova, Intracellular pH imaging in cancer cells in vitro and tumors in vivo using the new genetically encoded sensor SypHer2, *Biochim. Biophys. Acta* 1850 (2015) 1905–1911.
- [257] M. Damaghi, J.W. Wojtkowiak, R.J. Gillies, pH sensing and regulation in cancer, *Front. Physiol.* 4 (2013) 370.
- [258] B.A. Webb, M. Chimenti, M.P. Jacobson, D.L. Barber, Dysregulated pH: a perfect storm for cancer progression, *Nat. Rev. Cancer* 11 (2011) 671–677.
- [259] H.U. Bergmeyer, *Methods of Enzymatic Analysis*, Verlag Chemie Academic Press, 1974.
- [260] P. Rodriguez-Horche, J. Luque, E. Perez-Artes, M. Pineda, M. Pinilla, Comparative kinetic behaviour and regulation by fructose-1,6-bisphosphate and ATP of pyruvate kinase from erythrocytes, reticulocytes and bone marrow cells, *Comp. Biochem. Physiol. B* 87 (1987) 553–557.
- [261] H. Garreau, H. Buc-Temkine, Allosteric activation of human erythrocyte pyruvate kinase by fructose-1,6-diphosphate. Kinetic and equilibrium binding studies, *Biochimie* 54 (1972) 1103–1107.
- [262] K.E. Keller, I.S. Tan, Y.S. Lee, SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions, *Science* 338 (2012) 1069–1072.
- [263] O. Thalhammer, A. Pollak, G. Lubec, H. Konigshofer, Intracellular concentrations of phenylalanine, tyrosine and alpha-aminobutyric acid in 13 homozygotes and 19 heterozygotes for phenylketonuria (PKU) compared with 26 normals, *Hum. Genet.* 54 (1980) 213–216.